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ABSTRACT 
  
Methyl-CpG binding protein 2 (MECP2) is a widely abundant, multifunctional regulator of 
gene expression with highest levels of expression in mature neurons. In humans, both loss- and 
gain-of-function mutations of MECP2 cause mental retardation and motor dysfunction classified 
as either Rett Syndrome (RTT, loss-of-function) or MECP2 Duplication Syndrome (MDS, gain-of-
function). At the cellular level, MECP2 mutations cause both synaptic and dendritic defects. 
Despite identification of MECP2 as a cause for RTT nearly 16 years ago, little progress has been 
made in identifying effective treatments. Investigating major cellular and molecular targets of 
MECP2 in model systems can help elucidate how mutation of this single gene leads to nervous 
system and behavioral defects, which can ultimately lead to novel therapeutic strategies for RTT 
and MDS. In the work presented here, I use the fruit fly, Drosophila melanogaster, as a model 
system to study specific cellular and molecular functions of MECP2 in neurons. First, I show that 
targeted expression of human MECP2 in Drosophila flight motoneurons causes impaired dendritic 
growth and flight behavioral performance. These effects are not caused by a general toxic effect 
of MECP2 overexpression in Drosophila neurons, but are critically dependent on the methyl-
binding domain of MECP2. This study shows for the first time cellular consequences of MECP2 
gain-of-function in Drosophila neurons. Second, I use RNA-Seq to identify KIBRA, a gene 
associated with learning and memory in humans, as a novel target of MECP2 involved in the 
dendritic growth phenotype. I confirm bidirectional regulation of Kibra by Mecp2 in mouse, 
highlighting the translational utility of the Drosophila model. Finally, I use this system to identify a 
novel role for the C-terminus in regulating the function of MECP in apoptosis and verify this 
finding in mammalian cell culture. In summary, this work has established Drosophila as a 
translational model to study the cellular effects of MECP2 gain-of-function in neurons, and 
provides insight into the function of MECP2 in dendritic growth and apoptosis.  
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PREFACE 
This dissertation contains publications either previously published or in review for 
publication. The papers are a product of collaborative research with multiple co-authors. Here, I 
summarize my personal contribution to each publication.  
 In Chapter 2, I include a publication titled “Drosophila as a model for MECP2 gain-of-
function in neurons” by the authors Fernando Vonhoff, Alison Williams, Stefanie Ryglewski, and 
Carsten Duch published in the journal PLOS One in 2012. I contributed to the conception and 
design of the behavioral experiments described in this paper, executed the experiments, collected 
and analyzed the data, and contributed to the writing for this specific section. Stefanie Ryglewski 
designed, acquired, and analyzed the physiological data. Fernando Vonhoff conducted the 
cellular morphology experiments and analyzed data. Carsten Duch and Fernando Vonhoff 
conceived and designed the cellular experiments and wrote the paper.  
Chapter 3, “MECP2 impairs neuronal structure by regulating KIBRA” has been submitted 
for journal review by the authors Alison Williams, Robin White, Ashley Siniard, Jason 
Corneveaux, and Carsten Duch. I conceived and designed all experiments included in this 
publication, executed the experiments, collected and analyzed data, and wrote the manuscript. 
Robin White contributed to the conception and design of all mouse experiments, and assisted 
with Western blots of primary neuron cultures. Ashley Siniard prepared the libraries and 
conducted the RNA-Seq experiments, Jason Corneveaux analyzed the RNA-Seq data, and Matt 
Huentelman helped conceive and design the RNA-Seq experiments. Carsten Duch contributed to 
the conception and design of all included experiments and helped to write the manuscript. 
 Chapter 4,” MECP2 C-terminal truncating mutations cause neuronal apoptosis” has been 
submitted for journal review by the authors Alison Williams, Vera Mehler, Christina Mueller, 
Fernando Vonhoff, Robin White, and Carsten Duch. I conceived and designed most experiments 
included in the publication, executed the experiments, collected and analyzed data, and wrote the 
manuscript. Vera Mehler collected the cellular data with new MECP2 truncations, and helped with 
some subcloaning to generate new fly lines. Christina Mueller cultured and transfected HEK293T 
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cells. Fernando Vonhoff made the initial observation that inspired this work and collected the first 
data with the apoptosis reporter. Robin White contributed to the conception and design of the cell 
culture experiments. Carsten Duch contributed to the conception and design of all included 
experiments, collected some of the cellular data, and helped to write the manuscript.
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CHAPTER 1 
INTRODUCTION  
 Methyl-CpG binding protein 2 (MECP2) is a widely abundant, multifunctional regulator of 
gene expression with highest levels of expression in mature neurons (Kishi & Macklis, 2004). 
MECP2 was first discovered in 1992 in attempts to isolate methyl-CpG binding proteins to better 
understand how local DNA methylation prevents active transcription of genes (Lewis et al., 1992). 
The discovery of loss-of-function mutations as the cause of the X-linked neurodevelopmental 
disorder Rett syndrome (RTT) in 1999 (Amir et al., 1999), however, has steered research towards 
understanding how MECP2 disruption in the brain causes neurodevelopmental disease. In 2004, 
MECP2 duplications were implicated in a similar neurodevelopmental condition, later termed 
MECP2 duplication syndrome (MDS) (Van Esch et al., 2005) thus highlighting clinical 
consequences of both MECP2 gain- and loss-of-function.  
 
MECP2 Related Neurodevelopmental Disorders 
 RTT was first reported by the Austrian pediatrician Andreas Rett in 1966 (Rett, 1966), 
and is characterized by normal development during the first 6-18 months of life followed by a 
period of regression and onset of symptoms including gait abnormalities, loss of speech, 
repetitive hand stereotypies, and respiratory issues (Neul et al., 2010; Percy et al., 2010). RTT is 
one of the most common forms of X-linked mental retardation in females, occurring in 
approximately 1 in 10,000 live female births (Fombonne, Simmons, Ford, Meltzer, & Goodman, 
2001; Hagberg, 1985; Hagberg & Hagberg, 1997). The majority of loss-of-function MECP2 
mutations are paternally derived and therefore very rare in males (Trappe et al., 2001), although 
less severe MECP2 mutations have been identified in both males and females with varying 
degrees of intellectual disability and/or neuropsychiatric symptoms such as schizophrenia, ADHD, 
and bipolar disorder (Adegbola, Gonzales, Chess, LaSalle, & Cox, 2009; Cohen et al., 2002; 
Shibayama et al., 2004; Venkateswaran, McMillan, Doja, & Humphreys, 2014; Villard, 2007).  In 
contrast, gain-of-function mutations causing MDS affect primarily males, as females are often 
spared due to favorable X inactivation towards the non-mutated X chromosome (del Gaudio et 
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al., 2006; Van Esch et al., 2005). Males with MDS display symptoms similar to RTT, including 
severe intellectual disability, gait abnormalities, autistic features, seizures, hypotonia, and early 
death (Friez et al., 2006; Ramocki et al., 2009; Van Esch, 2011; Van Esch et al., 2005). 
Phenotypic features of MDS are dosage dependent, as more severe phenotypes are observed 
with triplication compared to duplication (Carvalho et al., 2011). Additionally, though female 
carriers are generally healthier than males with MDS, they do exhibit increased anxiety and 
depression (Ramocki et al., 2009) and, with less favorable X chromosome skewing, show mild 
intellectual disability and RTT like phenotypes (Grasshoff et al., 2011). 
 
RTT and MDS Pathology 
Analysis of post-mortem human brain tissue from RTT patients has revealed that RTT 
patient neurons are smaller, more densely packed (Bauman, Kemper, & Arin, 1995) and have 
reduced dendritic arborizations compared to healthy controls (Armstrong, Dunn, Antalffy, & 
Trivedi, 1995). In depth analysis of cortical and hippocampal pyramidal neurons has revealed 
fewer number of dendritic spines in RTT patients (Belichenko & Dahlström, 1995; Chapleau et al., 
2009) which, in combination with reduced dendritic arborizations, is indicative of fewer synaptic 
connections. Some effects occur only in select brain regions, as decreased dendritic complexity 
has been noted in motor, frontal, and inferior cortices, but not in visual cortex or hippocampus 
(Armstrong et al., 1995). MECP2 loss-of-function mouse models show similar reductions in 
dendritic complexity, neuronal size, and increased packing density (N. P. Belichenko, Belichenko, 
& Mobley, 2009; P. V. Belichenko et al., 2009; Fukuda, Itoh, Ichikawa, Washiyama, & Goto, 2005; 
Jentarra et al., 2010; Kishi & Macklis, 2004; Robinson et al., 2012; Tropea et al., 2009). As in 
humans, the structural changes can differ depending on the brain region (N. P. Belichenko et al., 
2009; P. V. Belichenko et al., 2009; Kishi & Macklis, 2004; Tropea et al., 2009; Wang, Reyes, & 
Zhou, 2013) and have also been reported to vary based on MECP2 mutation type and 
developmental time point (Wang et al., 2013).  
There are currently no published reports of neuronal pathology from MDS patients likely 
due to its rare occurrence, but evidence from model organisms suggests anatomical and 
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morphological features of MECP2 gain-of-function are similar to those occurring with loss-of-
function. Several in vitro studies with MECP2 gain-of-function in mouse primary neuron or slice 
cultures have shown reductions in dendritic arborization (Cheng et al., 2014; Zhou et al., 2006) 
and spine formation (Chapleau et al., 2009) and increases in neuronal apoptosis (Bracaglia et al., 
2009; Dastidar, Landrieu, & D'Mello, 2011). Evidence from MECP2 gain-of-function in vivo, 
however, has been less consistent. While overexpression of human MECP2 in the Xenopus 
tadpole visual system causes a similar reduction in complexity of dendritic arborization (Marshak, 
Meynard, De Vries, Kidane, & Cohen-Cory, 2012), these findings contrast reports from a MECP2 
gain-of-function mouse model (MECP2TG1) which found either increased dendritic arborization 
(Jiang et al., 2013) or no morphological changes (Wang et al., 2013) in pyramidal neurons 
compared to controls. Likewise, dendritic spine density is initially increased in early development, 
but is reduced in comparison to control mice by postnatal week 12 (Jiang et al., 2013).  
Similar neuronal pathology has been identified in a number of other neurodevelopmental 
diseases with associated mental retardation (Kaufmann & Moser, 2000; Kulkarni & Firestein, 
2012) and therefore likely contributes to the etiology of RTT and MDS. Accordingly, the decrease 
in spine density observed at postnatal week 12 correlates with the onset of behavioral symptoms 
in MECP2TG1 mice (Jiang et al., 2013), and a similar observation has been observed with loss-of-
function models. While pyramidal neurons from MECP2-/y  mice exhibit reduced dendritic 
complexity at both P30 and P60, the same neurons from MECP2T158A mice show reductions in 
dendritic complexity only at P60 (Wang et al., 2013). Both models represent MECP2 loss-of-
function mutations, but at P30 MECP2T158A are asymptomatic (Goffin et al., 2012) while MECP2-/y 
(Guy, Hendrich, Holmes, Martin, & Bird, 2001) have begun to show behavioral changes 
supporting the idea that decreased dendritic complexity accompanies RTT behavioral 
phenotypes. Accordingly, MECP2T158A exhibit behavioral changes by P60 (Goffin et al., 2012). It 
remains unclear, however, how MECP2 loss- or gain-of-function mutations cause changes to 
neuronal morphology and how these changes are related to the clinical manifestation of RTT and 
MDS. 
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MECP2 Structure and Function 
 MECP2 is traditionally known as a transcriptional repressor that binds to methylated CpG 
regions via the methyl binding domain (MBD) and silences local gene expression through the 
recruitment of histone deacytelase complexes mediated by the transcription repression domain 
(TRD) (Jones et al., 1998). Recent evidence, however, suggests that this is likely only one of 
many mechanisms by which MECP2 functions. MECP2 can bind other types of DNA 
modifications, including methylated CpA or CpT regions (Gabel et al., 2015; Guo et al., 2014) and 
5-hydroxymetylcytosines (5hmC) enriched within active genes (Mellen, Ayata, Dewell, 
Kriaucionis, & Heintz, 2012). Accordingly, MECP2 has also been shown to activate transcription 
in mouse models (Chahrour et al., 2008) although this function is only partially lost in the absence 
of DNA methylation (Chen, Shin, Thamotharan, & Devaskar, 2013). MECP2 can also bind non-
methylated DNA (Georgel et al., 2003; Ghosh et al., 2010; Hansen, Ghosh, & Woodcock, 2010; 
Nikitina et al., 2007) and other proteins to exert functions beyond the chromatin level, including 
RNA splicing (Young et al., 2006) and microRNA processing (Cheng et al., 2014). The degree to 
which the many described functions of MECP2 contribute to the pathogenesis of RTT or MDS, 
however, is not well understood. 
 
Animal Models of MECP2 Loss- and Gain-of-Function 
While multiple model systems are currently utilized to investigate the pathogenic 
mechanisms underlying RTT and MDS including Xenopus tadpoles (Marshak et al., 2012; 
Stancheva, Collins, Van den Veyver, Zoghbi, & Meehan, 2003), zebrafish (Pietri et al., 2013), and 
chicken (Petazzi et al., 2014), the majority of MECP2 related research has been conducted using 
mouse models of Mecp2 loss- and gain-of-function (Ezeonwuka & Rastegar, 2014). Mouse 
models recapitulate many RTT and MDS phenotypes and have been useful in understanding the 
complex cellular and behavioral defects caused by MECP2 dysfunction (Guy et al., 2001); 
however, the labor-intensive and complicated nature of work in genetic mouse models makes 
large scale screening and validation of functional cellular interactions in vivo expensive and time 
consuming.  
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Drosophila as a Model System of MECP2 Gain-of-Function 
The short generation time, facile genetic tools (Venken & Bellen, 2005), and high degree 
of conservation of fundamental cell biological pathways (Rubin et al., 2000) render the common 
fruit fly, Drosophila melanogaster, an attractive alternative model system to mouse models. While 
there is no known ortholog of MEPC2 in the Drosophila genome, a gain-of-function model has 
been established by heterologous expression of human MECP2 (Cukier et al., 2008). When 
expressed in Drosophila, human MECP2 associates with chromatin, interacts with orthologs of 
known interacting proteins, and is phosphorylated at the same sites in mammals (Cukier et al., 
2008). Furthermore, selective expression of human MECP2 in Drosophila neurons causes 
impairments in motor behavior (Cukier et al., 2008); however, the effects at the cellular level have 
not been explored. 
The primary goal of the research presented in this dissertation was to establish a 
Drosophila model of MECP2 gain-of-function in neurons and to utilize this model to investigate 
the pathogenic mechanisms by which MECP2 gain-of-function affects neuronal pathology. 
Drosophila was selected for this work for the following reasons: First, as mentioned above, 
genetic tools in Drosophila are unparalleled in other model systems. Transgenic flies are easily 
generated by injection of a DNA plasmid into the embryonic germline. Genomic integration is 
mediated by either P-element transposition (Craig, 1990), which results in random localization, or 
by site-specific integration strategies such as with phage PhiC31 integrase (Groth, Fish, Nusse, & 
Calos, 2004). These strategies have been used to create a wide range of genetic tools, for 
example, to visualize cells using fluorescent proteins, visualize neuronal activity with calcium 
sensitive indicators (Miyawaki et al., 1997; Tian et al., 2009), or to manipulate neuronal activity 
using channel rhodopsin mediated photoactivation (Zhang, Ge, & Wang, 2007) or expression of 
the TRPA1 temperature sensitive cation channel (Shang, Griffith, & Rosbash, 2008). The same 
system is often used for targeted manipulation of specific genes of interest, heterologous 
expression of non-Drosophila genes (Cukier et al., 2008; Lyko et al., 1999; Muqit & Feany, 2002),  
and for larger-scale resource projects, such as the development of genome-wide transgenic RNAi 
libraries (Dietzl et al., 2007). Combined with expression systems allowing controlled spatial and 
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temporal expression of transgenes, such as the binary UAS/GAL4 system adapted from yeast 
(Brand & Perrimon, 1993) and short generation time, these tools will allow rapid screening for 
cellular and molecular interactions relevant to phenotypes associated with MECP2 misregulation. 
Drosophila was additionally chosen for this work because of its proven track record for 
progressing human health related research. Despite its relative simplicity in comparison to human 
patients, research in Drosophila has enhanced our understanding of many human neurological 
conditions, including Fragile X, schizophrenia, addiction, Parkinson’s, Alzheimer’s, and 
Huntington’s diseases (Chan & Bonini, 2000; Chang et al., 2008; Kaun, Azanchi, Maung, Hirsh, & 
Heberlein, 2011; Kaun, Devineni, & Heberlein, 2012). While it is estimated that nearly 75% of 
disease-related genes in humans have functional fly orthologs (Reiter, Potocki, Chien, Gribskov, 
& Bier, 2001), Drosophila research has also yielded important data on the molecular function and 
cellular interactions of other disease-linked genes without Drosophila orthologs, including DISC1 
and α-synuclein (Auluck, Chan, Trojanowski, Lee, & Bonini, 2002; Sawamura et al., 2008). For 
example, expression of human α-synuclein in Drosophila helped identify Hsp70 as a genetic risk 
factor for Parkinson’s disease (Wu et al., 2004). Given this track record, it is anticipated that the 
investigation of human MECP2 in Drosophila neurons will help to advance understanding of RTT 
and MDS.  
Due to the lack of a common ortholog, it is not expected that expression of human 
MECP2 in the fly will recapitulate all pathophysiological features of gain-of-function in neurons. 
Furthermore, in comparison to humans, mice, and other higher level organisms, the Drosophila 
genome is scarcely methylated (Capuano, Mülleder, Kok, Blom, & Ralser, 2014; Dunwell & 
Pfeifer, 2014; Takayama et al., 2014) which could be an additional disadvantage when studying a 
protein with a known methyl-DNA binding function. As mentioned earlier, however, MECP2 can 
also bind non-methylated DNA and has other identified functions beyond the chromatin level. 
Using Drosophila could therefore still be useful in understanding the other functions of MECP2 as 
any observed effects are unlikely to be caused by the classic methy-CpG binding function. Thus, 
lack of DNA methylation in Drosophila may ultimately be an advantage in helping to decipher the 
links between molecular function of MECP2 and disease pathology.  
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Dissertation’s Focus 
  Despite many advancements into understanding the function of MECP2 in the brain 
throughout the last fifteen years, progress towards identifying effective treatments for RTT or 
MDS has been slow. Directly titrating MECP2 levels within the brains of patients is a poor option 
given the dysfunction associated with both loss- and gain-of-function (Amir et al., 1999; Van Esch 
et al., 2005) This approach is additionally complicated by the mosaicism of expression due to X-
inactivation in female RTT patients (Percy, 2002). Successful treatments should instead target 
genetic modifiers of MECP2 function and the affected neuronal processes; however, little is 
known about the molecular pathways disrupted by MECP2 loss- or gain-of-function.  
The purpose of this dissertation is to establish and utilize a Drosophila model to help 
understand the pathogenesis of neuronal pathology occurring specifically with MECP2 gain-of-
function. The research presented here thus aims to addresses the following questions: 
 
1) Can Drosophila be used as a model system to study MECP2 gain-of-function in neurons? 
(Chapter 2, 3, & 4) 
2) What are the molecular mechanisms underlying dendritic pathology caused by MECP2 gain-
of-function? (Chapter 3) 
3) What is the role of the MECP2 C-terminus in programmed cell death? (Chapter 4) 
4) Are new interactions identified with the Drosophila model translatable to systems with 
endogenous MECP2? (Chapter 3 & 4) 
 
In chapter 2, I present the initial validation work conducted in collaboration with other lab 
members in which we establish a Drosophila model of MECP2 gain-of-function in neurons. We 
tested the effects of heterologous MECP2 expression in identified Drosophila motoneurons on 
dendritic morphology, electrophysiology, and flight behavior. 
In chapter 3, I present findings utilizing the Drosophila model system established in 
chapter 2 to identify a novel player in the dendritic morphological defects associated with MECP2 
gain-of-function. Following identification in Drosophila, I used mouse primary neuron culture and 
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genetic models to validate the interaction between MECP2 and novel target KIBRA in a system 
with endogenous MECP2. 
In chapter 4, I present work conducted in Drosophila and in HEK293T cells to identify a 
role of the C-terminal domains in the apoptotic function of MECP2.  
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CHAPTER 2 
DROSOPHILA AS A MODEL FOR MECP2 GAIN OF FUNCTION IN NEURONS 
By Fernando Vonhoff, Alison Williams, Stefanie Ryglewski, and Carsten Duch 
PLoS ONE 7(2): e31835. doi:10.1371/journal.pone.0031835. 2012 
 
Abstract 
Methyl-CpG-binding protein 2 (MECP2) is a multi-functional regulator of gene expression. In 
humans loss of MECP2 function causes classic Rett syndrome, but gain of MECP2 function also 
causes mental retardation. Although mouse models provide valuable insight into Mecp2 gain and 
loss of function, the identification of MECP2 genetic targets and interactors remains time 
intensive and complicated. This study takes a step toward utilizing Drosophila as a model to 
identify genetic targets and cellular consequences of MECP2 gain-of function mutations in 
neurons, the principle cell type affected in patients with Rett-related mental retardation. We show 
that heterologous expression of human MECP2 in Drosophila motoneurons causes distinct 
defects in dendritic structure and motor behavior, as reported with MECP2 gain of function in 
humans and mice. Multiple lines of evidence suggest that these defects arise from specific 
MECP2 function. First, neurons with MECP2-induced dendrite loss show normal membrane 
currents. Second, dendritic phenotypes require an intact methyl-CpG-binding domain. Third, 
dendritic defects are amended by reducing the dose of the chromatin remodeling protein, osa, 
indicating that MECP2 may act via chromatin remodeling in Drosophila. MECP2-induced 
motoneuron dendritic defects cause specific motor behavior defects that are easy to score in 
genetic screening. In sum, our data show that some aspects of MECP2 function can be studied in 
the Drosophila model, thus expanding the repertoire of genetic reagents that can be used to 
unravel specific neural functions of MECP2. However, additional genes and signaling pathways 
identified through such approaches in Drosophila will require careful validation in the mouse 
model.  
 
 
 10 
Introduction 
Methyl-CpG-binding protein 2 (MECP2) is a multifunctional transcriptional regulator 
involved in chromatin remodeling. Loss of MECP2 function mutations cause classic Rett 
Syndrome (RTT) (Amir et al., 1999; Moretti & Zoghbi, 2006) an X-linked, dominant, progressive, 
neuro-developmental disorder (Hagberg, 1985; Percy, 2002). Patients with RTT suffer from 
cognitive, language, motor conditions, and seizures (Dunn & MacLeod, 2001; Hagberg, Aicardi, 
Dias, & Ramos, 1983). However, MECP2 duplication is a frequent case of mental retardation and 
progressive neurological symptoms in males (del Gaudio et al., 2006; Ramocki, Tavyev, & 
Peters, 2010; Van Esch et al., 2005) and overexpression of MECP2 in the developing mouse 
brain also causes progressive neurological disorder (Collins et al., 2004; Luikenhuis, Giacometti, 
Beard, & Jaenisch, 2004). 
The MECP2 protein contains at least five distinct functional domains (NTD, ID, MBD, 
TRD, and CTDα) which either bind DNA autonomously or regulate MBD (methyl-CpG binding) 
function (Ghosh et al., 2010). Historically, MECP2 is viewed as a transcriptional repressor that 
localizes to chromatin by binding to CpG dinucleotides to regulate gene expression through 
interactions with histone deacetylases and other cofactors (Jones et al., 1998; Nan, Campoy, & 
Bird, 1997; Nan, Meehan, & Bird, 1993; Nan, Tate, Li, & Bird, 1996). However, MECP2 can also 
activate transcription (Chahrour et al., 2008), associates also with un-methylated DNA (Ghosh et 
al., 2010; Ghosh, Horowitz-Scherer, Nikitina, Shlyakhtenko, & Woodcock, 2010; Yasui et al., 
2007), has chromatin compaction and RNA splicing functions (Harikrishnan et al., 2005; Jeffery & 
Nakielny, 2004; J. I. Young et al., 2005), and several MECP2 interacting proteins have been 
identified (Moretti & Zoghbi, 2006). Therefore, multiple MECP2 functions might be mediated by 
interactions with diverse co-factors and by binding to both methylated and non-methylated DNA, 
consistent with the wide range of phenotypes observed in patients with RTT.   
Although Mecp2 mouse models recapitulate RTT phenotypes (Armstrong, 2005; 
Armstrong et al., 1995; Bauman et al., 1995; Belichenko & Dahlström, 1995) and have provided 
valuable mechanistic insight into neuronal defects caused by Mecp2 mis-regulation, such as axon 
targeting (Matarazzo et al., 2004), synaptic (Asaka, Jugloff, Zhang, Eubanks, & Fitzsimonds, 
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2006; Moretti et al., 2006), and dendritic (Jentarra et al., 2010) defects, the identification of 
MECP2 functions and target genes in this system is time intensive and complicated.  
Facile genetic tools (Venken & Bellen, 2005), short generation times, and a high degree 
of conservation in fundamental cell biological pathways (Rubin et al., 2000) make Drosophila a 
powerful model to study molecular and cellular mechanisms underlying mental retardation (Bilen 
& Bonini, 2005; Gatto & Broadie, 2011; Restifo, 2005; Zhang & Broadie, 2005). It is not expected 
that Drosophila will recapitulate all details of Rett-related pathophysiology since its genome is 
sparsely methylated (Lyko & Maleszka, 2011) and does not contain an ortholog of human 
MECP2. However, multiple MECP2 interactors and most components of the chromatin machinery 
have well conserved orthologs in flies (Hendrich & Tweedie, 2003). In transgenic flies that 
express human MECP2, the protein associates with chromatin, modifies the transcription of 
multiple genes, and is phosphorylated at serine 423, as in mammals (Cukier et al., 2008). 
Significantly, reported consequences of a MECP2 gain-of-function in Drosophila are 
developmental defects and motor dysfunctions, suggesting close parallels with RTT phenotypes 
(Cukier et al., 2008). 
Our current study expands genetic and behavioral proof of principle for studying MECP2 
gain-of-function phenotypes in Drosophila (Cukier et al., 2008) to the level of central neurons. 
MECP2 expression in identified Drosophila motoneurons results in dendritic defects but normal 
membrane properties. MECP2-caused dendritic defects require an intact MBD domain, can be 
ameliorated by dose reduction of the chromatin remodeling protein osa, and cause specific motor 
behavioral defects, thus indicating that the Drosophila model is useful to unravel some aspects of 
MECP2 function in neurons.   
 
Methods 
Animals 
Drosophila melanogaster were reared in 68-ml vials on a standard yeast corn meal agar 
medium at 25°C and 50–60% humidity with a 12-h light/dark regimen. Flies were used for 
experiments 2 days after eclosion if not stated otherwise. Fly lines that carry different 
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permutations of the human MECP2 gene as UAS-transgenes were kindly provided by Dr. J Botas 
(Baylor College of Medicine, Houston, Texas) and were previously published (Cukier et al., 2008). 
The first transgene is full-length human MECP2, and the other ones show high frequencies of 
occurrence in patients with RTT. The R106W allele is a missense mutation in the methyl-CpG-
binding domain (MBD), thus eliminating the protein’s ability to bind methylated DNA (Yusufzai & 
Wolffe, 2000). In the 166 mutation the MBD and N-terminal portion of the protein are removed. 
Expression of UAS-MECP2 transgenes in the motoneuron, MN5, was realized by crossing to 
recombinant C380-GAL4, UAS-mCD8-GFP;; Cha-GAL80 flies which were obtained from Dr. S 
Sanyal (Emory University, Atlanta, GA), and have been described previously (Duch, Vonhoff, & 
Ryglewski, 2008; Hartwig, Worrell, Levine, Ramaswami, & Sanyal, 2008). C380 expresses in a 
subset of motoneurons including MN5, but also in some non-identified sensory neurons and 
interneurons (Boerner & Duch, 2010). Inclusion of the Cha-GAL80 transgene inhibited expression 
in cholinergic sensory neurons and interneurons, leaving expression in about thirty neurons per 
segment in the ventral nerve cord of Drosophila, most of which are motoneurons. Given this 
expression pattern, and the fact that insect motoneurons typically have no output synapses in the 
central nervous system (Burrows, 1996), phenotypes of individual neurons following the 
expression of UAS-MECP2 constructs under the control of C380-GAL4; Cha-GAL80 are likely to 
result from cell autonomous signaling. Therefore, possible indirect effects in motoneurons as 
resulting from altered neural network properties seem unlikely, although they can’t be fully 
excluded. All morphometric analysis was conducted with female flies. Control data derived from 
C380-GAL4, UAS-mCD8-GFP;; Cha-GAL80 crossed to w1118 flies and was consistent with 
quantitative dendritic architecture analysis of MN5 in multiple control strains which has previously 
been published (Vonhoff & Duch, 2010). Possible interactions between MECP2 and the 
chromatin remodeling trithorax protein, osa, were investigated by expressing human MECP2 
under the control of C380-GAL4 in a heterozygous mutant background for osa. Osa is a member 
of the SWI/SNF complex (human homolog is BAF250), a class of trithorax proteins involved in 
chromatin remodeling (Schuettengruber et al., 2007) which are highly conserved between flies 
and humans. Standard recombination protocols were used to cross C380-GAL4, UAS-mCD8-
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GFP;UAS-MECP2; Cha-GAL80 into an osa heterozygous mutant background (osa00090, loss of 
function allele, flybase ID: FBal0009367, fly strain 11486 from Bloomington (ry506 
PPZosa00090/TM3, ryRK Sb1 Ser1). 
 
Intracellular staining and histology 
Thin-walled borosilicate electrodes (resistance of 75–95 MΩ) with filament were used to 
stain the neurons. Electrode tips were filled with a mixture of 7% Neurobiotin (Linaris GmbH, 
Wertheim-Bettingen, Germany) and lysine fixable rhodamin-dextran 3000 (Invitrogen, Carlsbad, 
CA) in 2 M potassium acetate. To prevent dye dilution, an air bubble was left between the tip and 
the shaft. After intracellular penetration of MN5, the dye was injected iontophoretically by applying 
constant depolarizing current of 0.5 nA amplitude for 10–12 minutes. Subsequently, the electrode 
was removed and the ganglia were fixed in 4% paraformaldehyde in phosphate-buffer solution 
(PBS, 0.1M, pH 7.4) for 1 h at room temperature and washed in PBS. Preparations were washed 
6 x 30 min in 0.1 M PBS with 0.5% Triton X-100. This was followed by 8 washes, 15 minutes 
each in PBS.  Incubation in Cy3-Streptavidin in PBS (1:750, Invitrogen, Karlsruhe, Germany) was 
conducted over night at 4°C. Then, preparations were washed 6 x 15 min in PBS (0.1M). Then, 
the ganglia were dehydrated in an ascending ethanol-series (50, 70, 90, and 100%, 10 min each). 
Preparations were cleared and mounted in methyl salicylate. 
 
Electrophysiology 
See previous studies for detail (Ryglewski & Duch, 2009; Ryglewski, Lance, Levine, & 
Duch, 2012). Briefly, wings and legs were cut and the fly was then pinned dorsal side up in a 
sylgard coated Petri dish and submerged in normal saline (composition in mM: NaCl 128, KCl 2, 
CaCl2 1.8, MgCl2 4, HEPES 5, sucrose ~35 depending on the osmolality of the solution).  pH was 
adjusted to 7.25 with 1M NaOH. Osmolality was adjusted to 290 mOsM/kg with sucrose.  The 
animal was dissected along the dorsal midline, and the large dorsal longitudinal flight muscles 
were stretched laterally and pinned to expose gut, esophagus, and the ventral nerve cord (VNC) 
underneath. After removal of the gut and the esophagus, the VNC was exposed.  The head was 
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removed to facilitate electrode access to the mesothoracic neuromere.  For rapid saline exchange 
during experiments the volume of the recording chamber was minimized by placing a plexiglas 
ring (inner diameter 7mm) around the dissected animal and gluing it to the dish with petrolatum 
(volume of recording chamber was ~200µl).  The preparation was then mounted onto an upright 
fixed stage Zeiss Axioskop 2 FS plus fluorescence microscope (Zeiss, Germany) and viewed with 
a 40x water immersion objective. 
To facilitate access to MN5 with the patch pipette the ganglionic sheath was focally 
removed with a large patch pipette (0.5 M tip resistance) filled with 2% protease in buffer.  This 
was done under visual control of the flight motoneurons by fluorescent excitation of mCD8-GFP.  
After protease treatment, the preparation was rinsed with 60ml normal saline for 10 minutes. 
Following protease treatment and rinsing, one of the two available MN5s was recorded from with 
a patch pipette (tip-resistance 5.8-6.5 MΩ) pulled from borosilicate glass (o.d. 1.5 mm, i.d. 1.0 
mm without filament from World Precision Instruments) with a vertical pipette puller (Narishige 
Co., LTD., Japan).  For potassium current recordings electrodes were filled with normal internal 
solution with the following composition (in mM): Kgluconate 140, MgCl2 2, Mg-ATP 2, HEPES 10, 
EGTA 1.1, glucose to adjust osmolality to 300 mOsM/kg. The pH was adjusted to 7.25 with KOH.   
 
Immunohistochemistry 
Immunohistochemistry was performed as described previously (Boerner & Duch, 2010). 
MN5 intracellular stainings with neurobiotin were visualized by coupling to Cy3-streptavidin 
(1:1000) as described previously (Duch et al., 2008). Primary antibodies were Mouse anti-MECP2 
(1:1000, AbCam Ab50005), and mouse anti-GFP (1:400, AbCam Ab1218). The anti-MECP2 
antibody was raised against a C-terminal peptide of the MECP2 protein. However, 
immunostainings with an additional MECP2 antibody that was raised to detect phosphorylated 
serine 80 in the N-terminal domain of MECP2 (Symansis Cell Signaling Cat # SY-p1205-80) 
yielded identical results with regard to localization of MECP2 following targeted overexpression 
(not shown). Secondary antibodies were either Cy2 or Cy5-goat anti-mouse (1:1000). Incubation, 
dehydration, clearing and mounting were done as previously described (Boerner & Duch, 2010).   
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Confocal microscopy 
Digital images were captured with a Leica TCS SP2 confocal laser scanning microscope 
(Bensheim, Germany) using a Leica HCX PL APO CS x40 oil-immersion objective (numerical 
aperture: 1.2). Intracellular MN5 labeling with neurobiotin and subsequent coupling to Cy-3 
streptavidin were scanned with a krypton laser with an excitation wavelength of 568 nm. Emission 
was detected between 580 and 620 nm. Labels of anti-MECP2 were scanned by using a red 
HeNe laser at an excitation wavelength of 633 nm, and emission was detected between 640 and 
670 nm. Label of anti-GFP was excited with an argon laser at 488 nm and emission was detected 
between 495 and 530 nm. 
 
Geometric reconstructions and quantitative morphometry 
AMIRA 4.1.1 software (TGS) was used for processing of confocal image stacks. 
Geometric reconstructions were conducted with custom Amira plug-ins as developed in the Duch 
lab and described previously (Evers, Schmitt, Sibila, & Duch, 2005; Schmitt, Evers, Duch, Scholz, 
& Obermayer, 2004). Quantitative morphometric data were imported into Microsoft Excel software 
and Statistica (StatSoft, Hamburg, Germany) for further analyses. Mann-Whitney-U test was used 
for comparison of morphometric parameters between two different genotypes and one-way 
ANOVA was used to determine statistical significance between genotypes for branch order and 
Sholl analyses. For figure production, images were exported from AMIRA as tiff images and 
further assembled and labeled in figure panels with CorelDraw13 (Corel Corporation).   
The location of MN5 in the CNS is shown in figure 1A, and the overall structure of MN5 is 
depicted in figure 1B. MN5 is a unipolar cell, and its axon projects into the efferent nerve towards 
the DLM flight muscle on the contralateral side relative to the cell body. Consequently, axon and 
cell body are connected by a large primary neurite from which all major dendritic branches arise. 
To account for this feature in our morphometric analysis, we defined all dendritic branches 
originating from the primary neurite as first-order branches, virtually eliminating the primary 
neurite (which is treated as 0-order branch) between cell body and axon and therefore collapsing 
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the reconstruction onto one virtual origin. Every dendritic branch that branches off a first-order 
branch is defined as a second-order branch, and any branch branching off an n-order branch is 
defined as (n + 1)-order branch. 
 
Flight behavioral testing 
Behavioral testing was conducted as previously described (Brembs, Christiansen, 
Pflüger, & Duch, 2007) Briefly, one day old male flies were immobilized by cold anesthesia for 20 
s and glued (clear glass adhesive (Duro; Pacer Technology, Rancho Cucamonga, CA)) with head 
and thorax to a triangle-shaped copper hook (0.02 mm diameter). Adhesion was achieved by 
exposure to UV light for 30 s. The animals were then kept individually in small chambers 
containing a filter paper with 10µl of a 10% sucrose solution until testing (1–5 h). Then, the fly 
was attached to the experimental setup via a clamp to accomplish stationary flight. For 
observation, the fly was illuminated from behind and above (150 W, 15 V; Schott, Elmsford, NY) 
and fixed in front of a polystyrene panel. Additionally, it was shielded by another polystyrene 
panel from the experimenter. Tarsal contact with a bead of polystyrene prevented flight initiation 
before the experiment started. A digital high-speed camera (1000 pictures per second; Motion 
Scope; Redlake Imaging, Morgan Hill, CA) was positioned behind the test animal. To initiate 
flight, the fly was gently aspirated. The fly was aspirated as a stimulation to fly each time it 
stopped flying. When no flight reaction was shown after three consecutive stimulations, the 
experiment was completed and the total flight time was recorded (extended flight). Every stimulus 
after the first one, to which the fly showed a response, was recorded. The duration of each flight 
bout was recorded. Each fly was filmed during the first few seconds of flight, and the recordings 
were saved on a personal computer for later analysis. The person scoring the flight time was 
unaware of the treatment group of the animal. All animals were included in the study, including 
those that did not show any flight behavior.  
In some flight experiments, MN5 firing patterns were recorded extracellularly by inserting 
small tungsten wires (20µm diameter) into the dorsal most fiber of the DLM flight muscle (Duch et 
al., 2008). Extracellular potentials were amplified 100-fold (AM-Systems 1700), digitized with a 
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1401 analogue digital converter (Cambridge Electronic Design), and analyzed with Spike2 
software (Cambridge Electronic Design). 
 
Results 
This study used the individually identified flight motoneuron, MN5, to study effects of 
targeted expression of human MECP2 variants in Drosophila neurons on dendritic structure and 
membrane properties. As is the unique advantage of all individually identified neurons in 
invertebrate preparations, MN5 can be unambiguously identified in every individual fly, and it 
exhibits a characteristic morphology, membrane properties, and a distinct function albeit 
integrated into a network. MN5 is one of only five MNs innervating the dorsal longitudinal flight 
muscle (Fig. 1A, DLM) (Consoulas, Restifo, & Levine, 2002; Ikeda & Koenig, 1988) which 
provides the main force for wing downstroke during Drosophila flight. MN5 is a large monopolar 
neuron with its soma located in the mesothoracic neuromere of the Drosophila ventral nerve cord 
(VNC), on the contralateral side with respect to its target muscle (Fig. 1A), (Duch et al., 2008). All 
MN5 dendrites develop de novo during pupal life (Consoulas et al., 2002), thus allowing for 
studies of postembryonic dendritic growth. MN5 dendrites span the dorsal neuropil of the second 
thoracic neuromere of the Drosophila ventral nerve cord (Fig. 1A, dotted green line), and we have 
shown previously that MN5 dendritic structure shows reasonably low variation among control 
animals, which allows for quantitative studies of the effects of genetic manipulation (Vonhoff & 
Duch, 2010). In the adult fly, the dendritic field of MN5 comprises more than 4000 dendritic 
branches making up for more than 6500 m total length. In addition, we have analyzed firing 
responses (Duch et al., 2008) and membrane currents (Ryglewski & Duch, 2009)in control MN5. 
 We used the UAS-GAL4 system to express three different forms of human MECP2 using 
previously constructed transgenes (kindly provided by Dr. J Botas, Baylor College of Medicine, 
Houston, Texas) under the control of motoneuron-specific GAL4 drivers (C380-GAL4; see 
methods). The first is full-length human MECP2, and the other two are MECP2 alleles mutant in 
the MBD domain. The R106W allele is a missense mutation that creates a non-functional methyl-
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CpG-binding domain (MBD) (Yusufzai & Wolffe, 2000). In the 166 mutation the MBD and N-
terminal portion of the protein are removed.  
Full-length human MECP2 specifically causes dendritic defects but does not impair normal 
membrane excitability in Drosophila motoneurons.  
 Intracellular fills of MN5 in control animals with subsequent quantitative dendritic 
architecture reconstruction (Fig. 1B) yielded the same values for MN5 dendritic tree structure as 
previously published (Vonhoff & Duch, 2010), but expression of full-length human MECP2 in MN5 
clearly affected MN5 dendritic structure (Figs. 1C, D). Targeted expression of full-length human 
MECP2 in MN5 and few other neurons (see methods for expression patterns of C380-GAL4; 
Cha-GAL80) resulted in localization of MECP2 protein to the nuclei of these neurons, as 
demonstrated by MECP2 immunocytochemistry (Figs. 1D, E, magenta, see white arrow for MN5 
nucleus). Careful inspection of single optical sections through MN5 nucleus and dendrites (see 
inset in figure 1E) showed that no anti-MECP2 immunopositive label was detectable outside the 
nucleus. 
 Quantitative comparison of MN5 dendritic structure in controls (Fig. 1B) and following 
over-expression of MECP2 (Figs. 1C, D) caused a significant decrease in the number of 
branches by 60% (from 4000 ± 90 in controls to 1734.85 ± 713) which  resulted in significantly 
decreased total dendritic length by about 50% (Fig. 1F, from 6517 ± 471 µm in controls to 3490 
±816). By contrast, the mean lengths of the individual dendritic branches was slightly (20%) but 
significantly increased (Fig. 1F, from 1.69 ± 0.13 µm in controls to 2.04 ± 0.26 µm). Therefore, 
dendritic branch elongation was not impaired but new branch formation was strongly reduced by 
MECP2 expression. Average dendritic radii were also significantly increased following MECP2 
expression (Fig. 1F, from 0.23 ± 0.01 µm in controls to 0.26 ± 0.01 µm). However, dendritic 
territory borders were not affected as indicated by normal average distances of the dendrites to 
their origin (Fig. 1F, 17.7 ± 2.1 µm in controls and 16.5 ± 2.65 µm). Branch order analysis (Figs. 
1G, H) revealed that these dendritic phenotypes were not restricted to specific branch orders, 
indicating that MECP2 affected new dendritic branch formation and growth during all stages of 
postembryonic dendritic growth. Similar conclusions resulted from Sholl analysis which measures 
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dendritic lengths or dendrite numbers in concentric 3-dimensional spheres at different distances 
around the origin of the dendritic tree (not shown). MN5 dendritic defects as resulting from gain-
of-function of MECP2 were not a result of developmental delay because intracellular staining of 
MN5 in three, five, or ten days old adult flies did not reveal additional dendritic branches (not 
shown). By contrast, in progressively older flies MECP2-induced dendritic defects seemed 
increasingly more severe, although we did not quantify this observation.  
 Electrophysiological recordings in current and in voltage clamp mode showed that 
targeted expression of human MECP2 in MN5 did not affect firing properties or potassium 
membrane currents. Current clamp recordings revealed no obvious differences in MN5 firing 
responses to somatic current injections between controls and following MECP2 expression (Fig. 
2A). In situ voltage clamp recordings from MN5 under cadmium and TTX revealed no obvious 
differences in transient A-type or sustained delayed rectifier type voltage activated potassium 
currents in controls and following MECP2 expression (Figs. 2B, C). Quantification of A-type and 
delayed rectifier potassium currents revealed no significant differences in I/V–relationships 
between controls and following MECP2 expression (Fig. 2C). In sum, over-expressed human 
MECP2 localized to the nucleus in a Drosophila motoneuron and significantly impaired new 
dendrite formation resulting in a reduction of total dendritic length by 50 percent. However, full-
length MECP2 did not affect normal development of membrane excitability, did not alter dendritic 
territory borders, and did not impair dendritic branch elongation. This indicated that over-
expression of MECP2 specifically impaired dendritic branching but did not have overall 
deleterious effects on motoneuron physiology. 
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Figure 1. Heterologous expression of MECP2 causes dendritic defects in Drosophila 
motoneurons. 
 (A) Schematic drawing of location of MN1-5 in the Drosophila nervous system and their 
innervation of the dorsal longitudinal flight muscle (DLM) fibers. MN5 is depicted in green, and 
MN5 dendritic projection in the dorsal mesothoracic neuromere is demarked by a dotted green 
line (B) Overview of MN5 structure in a representative control animal. A geometric reconstruction 
of MN5 dendritic structure is superimposed on the projection view. (C) Overview of MN5 dendritic 
structure following targeted expression of full-length human MECP2. Geometric reconstruction 
superimposed on projection image of MN5. (D) Double staining of MN5 (green) and anti-MECP2 
immunolabeling (magenta) shows MECP2 localization to MN5 nucleus (white) and some other 
nuclei of neurons with C380-GAL4/UAS-MECP2 expression. (E) Same as (D) but anti-MECP2 
immunolabeling only to show that no MECP2 protein was detected through MN5 processes. Inset 
depicts anti-MECP2 immunostaining in a representative single optical section through MN5 soma 
and primary neurite. MN5 outline is demarked by white line, and white arrow demarks MN5 
nucleus. MECP2 protein could not be detected in any part of MN5 except the nucleus. (F) 
Quantitative metric measures of dendritic structure in MN5 from controls (gray bars) and in MN5 
with MECP2 expression (magenta). Values are normalized to mean control values (dotted line). 
Arrows indicate statistical significant differences (Students T-test, p ≤ 0.01). Error bars indicate 
standard deviation. (G and H) Mean number of dendritic branches (G) and mean dendritic radius 
in controls (gray squares) and following MECP2 expression (magenta circles) over branch order. 
Error bars indicate standard deviation. Axis in (H) is clipped at branch order 41 because only few 
dendrites of higher branch orders exist (see G).  
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Figure 2. Heterologous expression of MECP2 does not affect electrophysiological 
properties of Drosophila motoneurons.  
(A) Comparison of typical MN5 firing responses to 300 pA of somatic current injection in a 
representative control animal (left trace) and following targeted expression of full-length human 
MECP2 under the control of C380-GAL4 (right trace). (B) Voltage dependent potassium currents 
in MN5 as induced by command voltage steps from a holding potential of -90 mV to 20 mV in 
increments of 10 mV and with cadmium and TTX in the bath solution to block sodium and calcium 
inward currents. Traces of control animals (left) and following targeted expression of MECP2 
(right) reveal qualitatively similar transient A-type current and sustained delayed rectifier like 
potassium outward currents. (C) Current/Voltage relationships for A-type (left) and sustained 
delayed rectifier (right) potassium currents are quantitatively similar in controls (gray diamonds) 
and following expression of MECP2 (magenta diamonds). Error bars represent standard 
deviations.    
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Dendritic defects caused by human MECP2 in Drosophila motoneurons require normal 
MBD function 
 Next, we confirmed that dendritic defects as caused by targeted expression of human 
MECP2 in Drosophila motoneurons were dependent on known molecular functions for MECP2, 
and not due to non-specific effects that can potentially result from the expression of a non-
endogenous protein. To test whether normal MECP2 protein function was required for the 
observed effects on dendrite development, we expressed two MECP2 transgenes with non-
functional methyl-CpG-binding domains (MBD; Fig. 3A) in MN5 under the control of the same 
C380-GAL4 driver that yielded dendritic defects when used to express full-length MECP2. MBD 
domains are required for the two key mechanisms of chromatin regulation in eukaryotes, C5 
methylations of DNA at cytosines and posttranslational histone modifications (Bartke et al., 2010). 
Expression of UAS-MECP2 with either a mis-sense mutation that creates a non-functional MBD 
(Fig. 3B; R106W allele) (Yusufzai & Wolffe, 2000), or with a truncated MBD and N-terminal 
portion (Fig. 3C; 166 allele) did not cause any obvious dendritic defects (Figs. 3B to G). As for 
full-length MECP2 (see above) strict nuclear localization of MECP2 was observed for the R106W 
and the 166 alleles (Figs. 3D, E; see also white arrows in figures 3B, C). Quantification of total 
dendritic length (Fig. 3H) and the number of dendritic branches (Fig. 3I) demonstrated that no 
significant differences existed between controls or following targeted expression of MECP2 with 
defective MBD (Figs. 3H, I; ANOVA with Newman Keuls post hoc testing, p > 0.2). By contrast, 
expression of full-length human MECP2 caused less total dendritic length (Fig. 3H) and 
significantly fewer branches (Fig. 3I) than expression of either R106W or 166 (ANOVA with 
Newman Keuls post hoc testing, p < 0.01). Therefore, dendritic phenotypes induced by targeted 
expression of human MECP2 in Drosophila neurons required an intact MBD, indicating specific 
action and not unspecific toxic effects of MECP2 gain-of-function in Drosophila motoneurons. 
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Figure 3. Heterologous expression of MECP2 with MBD defects does not affect Drosophila 
motoneuron dendrite development 
(A) Schematic drawings of full-length human MECP2 (magenta) with intact methyl-CpG-binding 
domain (MBD) and intact transcriptional repression domain (TRD). The R106W mutation (red) 
carries a point mutation (see x) that causes a non-functional MBD. The 166 mutation (orange) 
has a truncated MBD and N-terminus. TRD is intact in all three alleles. Nuclear localization 
sequences (nls) have been reported in the inter-domain region at residues 174 and 190 and also 
in the TRD domain between residues 255 and 271, and are intact in all three alleles. (B, D, F) 
Intracellular labeling of MN5 following R106W expression under the control of C380-GAL4 (B) 
and subsequent geometric reconstruction (F) do not reveal obvious dendrite defects in MN5. (D) 
MECP2 immunolabeling following targeted R106W expression indicates strict nuclear localization 
(see also white arrow in B). (C, E, G) Intracellular labeling of MN5 following 166 expression 
under the control of C380-GAL4 (C) and subsequent geometric reconstruction (G) do not reveal 
obvious dendrite defects in MN5. (E) MECP2 immunolabeling following targeted R106W 
expression indicates strict nuclear localization (see also white arrow in C). (H) Averages of total 
dendritic length in controls (gray bars), and following expression of full-length MECP2 (magenta), 
R106W (red), and 166 (orange). (I)  Average numbers of dendritic branches in controls (gray 
bars), and following expression of full-length MECP2 (magenta), R106W (red), and 166 
(orange). In (H) and (I) error bars indicate standard deviation, asterisks demark statistical 
significance at p ≤ 0.05 (ANOVA with Newman Keuls posthoc test).  
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Dendritic defects in Drosophila motoneurons caused by gain-of-function of human MECP2 
can be ameliorated by reducing the dose of the BAF250 homolog, osa 
 Since Drosophila DNA is only sparsely methylated, interactions of the MBD of MECP2 
with C5 methylations of DNA at cytosines seem unlikely (see discussion). Alternatively, the 
MECP2 MBD might interact with posttranslational histone modifications (Bartke et al., 2010). This 
is in agreement with previous findings that reduction of osa function can amend behavioral 
defects as induced by pan neuronal expression of human MECP2 in flies (Cukier et al., 2008). 
Osa (human homolog is BAF250) is a member of the SWI/SNF complex, a class of trithorax 
proteins involved in chromatin remodeling (Schuettengruber, Chourrout, Vervoort, Leblanc, & 
Cavalli, 2007). To test whether MECP2-induced dendritic defects require normal function of an 
intact BAF complex (ATP-dependent chromatin remodeling complex) we expressed full-length 
human MECP2 in MN5 in a heterozygous osa mutant background, which should lower the dose 
of functional osa protein. Intracellular labeling of MN5 in a heterozygous osa mutant background 
(Fig. 4B) and subsequent quantification (Fig. 4E) showed that a reduction in osa dose did not 
alter dendritic structure as compared to controls (Figs. 4A, E). However, the heterozygous osa 
mutant background significantly ameliorated MECP2-induced dendritic effects in MN5 (Figs. 4 C, 
E, F). The strict nuclear localization of MECP2 was not altered by a reduction in osa function (Fig. 
4D). Although total dendritic length and the number of dendrites were significantly lower as 
compared to controls, MN5 contained significantly more dendrites and a larger total dendritic 
length if expressed in the presence of reduced osa function as compared to expression of 
MECP2 in controls (Fig. 4E). Therefore, dendritic defects as caused by MECP2 gain-of-function 
can be partially rescued by a reduction in osa function, thus indicating functional interactions of 
MECP2 and osa. This was also reflected by branch order analysis. Expression of full-length 
human MECP2 in an osa heterozygous mutant background resulted in fewer dendrites through all 
branch orders higher than eight as compared to controls (Fig. 4F), but it resulted in more 
dendrites per branch order as compared to expression of full-length MECP2 in a wild type 
background (Fig. 4F). By contrast, increased mean length and radius of individual dendritic 
branches as induced by targeted expression of MECP2 were not rescued in an osa mutant 
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background.  In sum, these genetic interaction experiments show that MECP2-induced MN5 
dendritic branch formation defects require normal osa function, indicating that the MB domain of 
MECP2 may interact with the ATP-dependent chromatin remodeling BAF complex (see 
discussion).  
Motor behavioral consequences of MECP2-induced dendritic defects 
 Human RTT patients suffer from motor deficits, and mouse models recapitulate motor 
dysfunctions. Similarly, Cukier et al. (Cukier et al., 2008) reported that expression of full-length 
human MECP2 in all cholinergic neurons leads to impaired motor function in a climbing assay. 
We tested whether MECP2-induced motoneuron dendritic defects affected motor performance of 
adult flies. First, it is favorable to have an easy to score phenotype to screen potential genetic 
rescues in future experiments. Second, it is important to test what the functional consequences of 
the specific dendritic defects reported in this study are. As mentioned above, MN5 is one out of 
five flight motoneurons innervating the dorsal longitudinal flight muscle (DLM, Fig. 1A). In our 
experiments, MECP2 was expressed in MN1-5. Therefore, we tested for flight behavioral defects. 
First, MN5 firing patterns were recorded extracellularly with fine tungsten wires during restrained 
flight (see methods) (Duch et al., 2008).  Since Drosophila flight is powered by asynchronous 
flight muscles MN1-5 fire only at about every 10th to 20th wingbeat (Dickinson & Tu, 1997). No 
obvious differences were found between MN5 firing patterns during flight in control animals as 
compared to animals with MECP2 expression in MN1-5 (Fig. 5A). Similarly, wing beat 
frequencies during flight were not different between both groups (Fig. 5B). Moreover, the 
likelihood to engage into a flight was not affected by MECP2-induced motoneuron dendritic 
defects (Figs. 5C, D). Neither the percentage of flies taking off in response to a wind stimulus 
(Fig. 5C), nor the number of flight bouts that could be elicited in flies were different between 
controls and MECP2 expressing flies. By contrast, flies with MECP2-caused motoneuron 
dendritic defects could not maintain flight motor behavior. The mean duration per flight bout (Fig. 
5E) was drastically reduced in MECP2 flies as compared to control flies, on average by a factor of 
60. Similarly, total flight duration was significantly reduced in animals with MECP2-caused 
motoneuron dendritic defects (Fig. 5F), on average by a factor of 30. 
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Figure 4. MECP2-caused dendrite defects are partially ameliorated by a reduction in osa 
dose.  
(A) Projection view of a representative intracellular staining of MN5 in a control animal. (B) 
Projection view of a representative intracellular staining of MN5 in an osa heterozygous mutant 
background does not reveal obvious differences in dendritic structure as compared to control. (C) 
Projection view of a representative intracellular staining of MN5 with heterologous expression of 
full-length MECP2 in an osa heterozygous mutant background does not show similar dendritic 
defects as compared to MECP2 expression in a wildtype osa background (see figures 1C, D). (D) 
MECP2 immunopositive label (magenta) was restricted to the nucleus (see also white arrow in 
C). (E) Quantitative metric measures of dendritic structure in MN5 from controls (dark gray bars), 
MN5 in an osa heterozygous mutant background (light gray bars), from MN5 with MECP2 
expression (magenta), and from MN5 with MECP2 expression in an osa heterozygous mutant 
background. Values are normalized to mean control values. Arrows indicate statistical 
significance (ANOVA with Newman Keuls posthoc test, p ≤ 0.01). Error bars indicate standard 
deviation. (F) Mean number of dendritic branches over branch order in controls (gray squares), 
following MECP2 expression (magenta circles), and following MECP2 expression in an osa 
heterozygous mutant background (blue). Error bars indicate standard deviation.  
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Figure 5. MECP2-induced motoneuron defects result in specific motor behavioral 
deficiencies. 
 (A) Representative extracellular recording of MN5 firing patterns during flight in a control (upper 
trace) and in fly expressing MECP2 in a subset of neurons, including MN5 (C380-GAL4, UAS-
mcd8-GFP;; Cha-GAL80 / UAS-MECP2; lower trace). Traces above the recordings resemble 
spike counts. Black arrow demarks start of flight, and black asterisk demarks time point of flight 
stop in MECP2 fly. (B) Average in-flight wing beat frequencies of control (white bar) and MECP2 
flies (grey bar). Error bars represent standard error. (C) Percentage of control (white bar) and 
MECP2 flies (grey bar) engaging into flight upon a wind stimulus. (D) Numbers of flight bouts 
performed by control (white bar) and by MECP2 flies (grey bar) in response to re-occurring wind 
stimuli (see methods). Data are presented as median and quartiles. Error bars represent 
minimum and maximum values. (E and F) Total duration of all consecutive flight bouts (E) and 
average duration of individual flight bouts (F) in control (white bar) and in MECP2 flies (grey bar). 
Data are presented as median and quartiles. Error bars represent minimum and maximum 
values. ** demarks p < 0.01, Mann and Whitney U-test.  
 28 
Discussion 
Drosophila as a useful genetic model for studies on MECP2 gain-of-function in neurons 
The Drosophila genetic model system is experiencing increasing use as a tool to analyze 
specific genetic and cellular aspects of neurodevelopmental disorders. Short generation times, 
high fecundity, high throughput screening techniques, facile genetic tools, and relatively low costs 
have provided valuable mechanistic insights into inherited diseases like Fragile-X, Angelman 
syndrome, and neurofibromatosis (Gatto & Broadie, 2011). However, despite considerable 
conservation in fundamental cell biological pathways the Drosophila genome encodes only about 
75 percent of human disease associated genes (Reiter et al., 2001), and mecp2 is not among 
these genes. Therefore, Drosophila cannot be used to study the pathophysiology resulting from 
loss of endogenous mecp2. Instead, the Drosophila model relies on heterologous expression of 
human MECP2 allele and consequential gain of MECP2 function. Although classic Rett is mostly 
caused by loss-of-function of MECP2, this is likely not an artificial approach since in humans and 
in mouse models increased levels of MECP2 also cause disease (Collins et al., 2004; del Gaudio 
et al., 2006; Luikenhuis et al., 2004; Ramocki et al., 2010; Van Esch et al., 2005). Genetic and 
behavioral proof of principle for the use of the Drosophila model to address MECP2 gain-of-
function has recently been provided (Cukier et al., 2008). In MECP2 transgenic flies the MECP2 
protein associates with chromatin, interacts with homologs of known human MECP2 interactors, 
modifies the transcription of multiple genes, and is phosphorylated at serine 423, as in mammals. 
Most importantly, reported consequences are developmental dysfunctions and motor defects, 
suggesting parallels with RTT phenotypes. However, previous work on MECP2 in the Drosophila 
CNS has not tested for cellular phenotypes resulting from MECP2 over-expression in neurons, 
although mouse models have demonstrated that disease phenotypes result from Mecp2 mis-
regulation in postmitotic neurons (Luikenhuis et al., 2004). This study presents the first data on 
cellular defects as resulting from MECP2 gain-of-function in developing postmitotic Drosophila 
neurons. 
 Our data demonstrate that heterologous expression of human MECP2 in Drosophila 
motoneurons does not affect axonal pathfinding, dendritic territory boundaries, or the neurons´ 
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electrophysiology, but it causes a significant reduction in new dendritic branch formation during 
development. Similarly, in the mouse model Mecp2 mis-regulation results in pyramidal neuron 
dendritic defects (Jentarra et al., 2010; Moretti et al., 2006). We provide four lines of evidence 
that dendritic defects in Drosophila motoneurons are caused by specific cellular functions that 
result from MECP2 gain-of-function, and not from non- specific over-expression or sequestering 
effects. First, MECP2 protein specifically localizes to the nucleus of Drosophila neurons, so that 
interactions of MECP2 with molecules in the cytoplasm are unlikely. Second, targeted expression 
of MECP2 in Drosophila motoneurons causes significant dendritic branching defects but does not 
affect firing responses to current injections, voltage activated potassium current, or firing 
frequencies during motor behavior, indicating normal regulation of electrophysiological properties. 
Although it has recently been demonstrated that Drosophila motoneuron dendritic structure may 
undergo compensatory changes in response to altered neuronal activity (Tripodi, Evers, Mauss, 
Bate, & Landgraf, 2008), and a link between motoneuron activity and dendritic growth has clearly 
been established (Duch et al., 2008; Hartwig et al., 2008), we did not find any evidence for 
homeostatic changes in motoneuron excitability in response to developmental defects in dendritic 
structure. Third, MECP2-induced dendritic defects require intact MBD function of the MECP2 
protein because dendritic architecture was not affected following expression of MECP2 alleles 
with non-functional MBD. This indicates that human MECP2 exerts specific action in Drosophila 
neurons via chromatin remodeling (see below). Fourth, MECP2-induced dendritic phenotypes can 
be ameliorated by reducing the dose of osa, a member of the SWI/SNF complex. This genetic 
interaction experiment is consistent with the hypothesis that human MECP2 may exert specific 
action in Drosophila motoneurons via chromatin remodeling. It also indicates that MECP2 gain-of-
function activates specific cell signaling pathways in Drosophila, and may not cause unspecific 
over-expression effects. Therefore, we conclude that Drosophila neurons can serve as a valuable 
model system to identify some cellular mechanisms by which MECP2 gain-of-function affects 
neuronal development.  
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Potential mechanisms underlying MECP2-induced dendritic defects in Drosophila neurons 
Our data indicate that dendritic defects as induced by heterologous expression of MECP2 
in Drosophila motoneurons require an intact MBD domain, because expression of MECP2 with a 
point mutated or truncated MBD domain has no effects on dendritic structure. However, each 
UAS-MECP2 transgene is likely inserted into a unique site in the Drosophila genome, and 
therefore, we can’t exclude the possibility that different UAS-MECP2 transgenes may yield 
different expression levels or other genetic interactions. For two reasons we judge it unlikely that 
our finding that dendritic defects as caused by the expression of full length UAS-MECP2, but not 
by the expression of UAS-MECP2 transgenes with defective MBD domain, were a result of the 
unique insertion sites of the UAS-MECP2 constructs into the Drosophila genome.  First, both 
UAS-transgenes with defective MBD did not cause dendritic defects. Second, similar dendritic 
defects were observed following the expression of the full length MECP2 construct inserted in the 
second or in the third chromosome. 
MBD domains recognize the two key mechanisms of chromatin regulation in eukaryotes, 
C5 methylations of DNA at cytosines and post-translational histone modifications (Bartke et al., 
2010). Although the existence of DNA methylation has been demonstrated in the fly genome 
(Gowher, Leismann, & Jeltsch, 2000; Lyko, Ramsahoye, & Jaenisch, 2000), methylation levels 
are several orders of magnitude lower than in mammals. The fly genome contains only one 
methylated DNA binding protein (dMBD2/3) and only one DNA methyltransferase (dDNMT2), 
which shows highest affinity to t-RNA. Consequently, Drosophila DNA is only sparsely 
methylated, so that MECP2 interactions with modified histone tails seem the more parsimonious 
scenario. This is consistent with our finding that MECP2-dependent dendritic defects are 
suppressed in an osa heterozygous mutant background. Osa is a member of the SWI/SNF 
complex (human homolog is BAF250), a class of trithorax proteins involved in chromatin 
remodeling (Schuettengruber et al., 2007) which are highly conserved between flies and humans. 
This indicates that human MECP2 may exert specific action in Drosophila motoneurons via 
chromatin remodeling. In fact, it has previously been suggested that MECP2 associates with 
human Brahma, a catalytic component of the SWI/SNF chromatin remodeling complex to regulate 
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gene repression (Harikrishnan et al., 2005), although this finding has been disputed (K. Hu, Nan, 
Bird, & Wang, 2006). The Drosophila system provides some unique advantages to study possible 
interactions of MECP2 and members of the SWI/SNF chromatin remodeling complex with genetic 
tools.  
 
MECP2-induced motoneuron dendritic defects cause specific motor behavioral 
deficiencies 
Our findings that flies with MECP2 over-expression in motoneurons show normal take-off 
likelihoods as well as normal motoneuron firing and wing beat frequencies, but cannot sustain 
flight are in accord with specific MECP2 effects on dendrite development in otherwise normal 
motoneurons. In Drosophila, take-off can be mediated by the escape response neural circuitry. 
This circuitry bypasses flight motoneuron dendrites by synapsing directly on MN5 axon, but it 
relies on normal synaptic transmission and flight motoneuron physiology (Allen, Drummond, & 
Moffat, 1998; Fayyazuddin, Zaheer, Hiesinger, & Bellen, 2006). Therefore, initial take-off and 
initial motoneuron firing are not affected by dendritic defects. In Drosophila motoneuron firing 
frequencies are directly proportional to wing beat frequency (Gordon & Dickinson, 2006), and 
thus, these are also not affected. By contrast, flight cannot be sustained because the significantly 
reduced dendritic surface likely reduces the excitatory synaptic drive to motoneuron dendrites (C. 
Duch & Mentel, 2004) that is necessary to stay in flight. Therefore, flies with MECP2-caused 
motoneuron dendritic defects show a 30- to 60-fold reduction in flight duration. This behavioral 
phenotype is obvious, and thus, useful for screening. Although the quantification of flight 
durations and take-off likelihoods as presented in figure 5 does not allow for rapid genetic 
screening, high throughput screening can easily be developed based on the observed reduction 
in flight duration by more than 30-fold.  Moreover, high throughput assays which utilize Drosophila 
behavior for rapid screening have been developed by others (Branson, Robie, Bender, Perona, & 
Dickinson, 2009; Fry, Rohrseitz, Straw, & Dickinson, 2008). Such approaches may help the future 
identification of candidate MECP2 targets or interactors. 
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The use of Drosophila to identify candidate pathways for non-methylated DNA-dependent 
functions of MECP2 in neurons 
Historically MECP2 is viewed as a transcriptional repressor that localizes to chromatin by 
binding to CpG dinucleotides to regulate gene expression by interactions with histone 
deacetylases and other cofactors (Jones et al., 1998; Nan et al., 1997; Nan et al., 1993; Nan et 
al., 1996). However, MECP2 also binds to genes that are actively transcribed (Chahrour et al., 
2008), can associate widely with un-methylated DNA (Ghosh et al., 2010; R. P. Ghosh et al., 
2010; Yasui et al., 2007), interacts with multiple other proteins (Moretti et al., 2006), and has 
chromatin compaction and RNA splicing functions (Jeffery & Nakielny, 2004; Young et al., 2006). 
Therefore, multiple MECP2 functions might be mediated by interactions with diverse co-factors 
and by binding to both methylated and non-methylated DNA. Identification of genetic interactors 
and modifiers of MECP2 function in neurons will be imperative toward developing future 
treatment strategies. MECP2 itself is not a promising treatment target because the X-linked 
MECP2 gene is mosaic regulated in the human brain. Furthermore, both loss and gain of function 
cause disease phenotypes. The sparse methylation landscape in Drosophila may offer unique 
promise of identifying non-methylated DNA-dependent functions of MECP2 in neurons, the cell 
type that is most relevant to Rett syndrome. Since known binding partners of MECP2 are 
conserved in flies (e.g. YB-1, mSin3A etc.), it seems plausible that gain-of-function of human 
MECP2 may affect neural development via a cellular machinery that is partly conserved between 
flies and humans. 
MECP2-induced dendritic phenotypes in flight motoneurons cause a severe motor 
behavioral phenotype in that flight bout duration is reduced approximately 30- to 60-fold. Rapid 
screening assays for Drosophila behavioral phenotypes are available (Branson et al., 2009; Fry et 
al., 2008). Combined with the fast generation times, high fecundity and facile genetic tools 
available in Drosophila this offers a powerful tool to identify molecules that interact with MECP2 in 
neurons. However, potential MECP2 candidate target genes or genetic modifiers of MECP2 
function that can readily be identified in the Drosophila system will then have to be further 
evaluated in the existing mouse models of RTT.    
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CHAPTER 3 
 
MECP2 IMPAIRS NEURONAL STRUCTURE BY REGULATING KIBRA 
By Alison Williams, Robin White, Ashley Siniard, Jason Corneveaux,   
Matt Huentelman, & Carsten Duch 
Abstract 
Using a Drosophila model of MECP2 gain-of-function, we identified memory associated KIBRA as 
a target of MECP2 in regulating dendritic growth. We found that expression of human MECP2 
increased kibra expression in Drosophila, and targeted RNAi knockdown of kibra in identified 
neurons fully rescued dendritic defects as induced by MECP2 gain-of-function. Validation in 
mouse confirmed that Kibra is similarly regulated by Mecp2 in a mammalian system. We found 
that Mecp2 gain-of-function in cultured mouse cortical neurons caused dendritic impairments and 
increased Kibra levels. Accordingly, Mecp2 loss-of-function in vivo led to decreased Kibra levels 
in hippocampus, cortex, and cerebellum. Together, our results functionally link two neuronal 
genes of high interest in human health and disease and highlight the translational utility of the 
Drosophila model for understanding MECP2 function. 
 
Introduction 
Methyl-CpG binding protein 2 (MECP2) is a widely abundant, multifunctional regulator of 
gene expression with highest levels of expression in mature neurons. In humans, both loss- and 
gain-of-function mutations of MECP2 cause mental retardation and motor dysfunction classified 
as either Rett Syndrome (RTT, loss-of-function) (Amir et al., 1999) or MECP2 Duplication 
Syndrome (MDS, gain-of-function) (Ramocki et al., 2010). In patients and in mouse models both 
MECP2 loss- and gain- of function can cause changes in dendritic morphology (Armstrong, 2005; 
Cheng et al., 2014; Wang et al., 2013; Zhou et al., 2006). While there is no MECP2 ortholog in 
Drosophila, we recently found that expression of human MECP2 (hMECP2) severely reduces the 
dendritic complexity of identified Drosophila motoneurons while maintaining normal membrane 
currents (Vonhoff, Williams, Ryglewski, & Duch, 2012). 
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Short generation times, facile tools for genetic manipulation (Venken & Bellen, 2005), and 
a high degree of conservation in fundamental cell biological pathways involved in neuronal 
development (Degerny, Wang, Xu, & Yang, 2009; Louvi & Artavanis-Tsakonas, 2006; Rubin et 
al., 2000) make Drosophila a powerful model to study the cellular and molecular mechanisms by 
which MECP2 acts to impact dendritic structure. Because the Drosophila genome contains low 5-
methylctosine (5’mC) levels (Capuano et al., 2014), it is not expected that this system can be 
used to elucidate mechanisms associated with the classical 5’mCpG dependent transcription 
repression function of MECP2 (Nan et al., 1997). However, MECP2 has also been shown to 
activate transcription (Chahrour et al., 2008) and many additional cellular function of MECP2 
have been identified which do not require binding to methylated DNA (Cheng et al., 2014; 
Georgel et al., 2003; Hansen et al., 2010; Skene et al., 2010; Young et al., 2006). Further, other 
proteins with methyl binding domains (MBD) exist in Drosophila, and many MECP2 interactors, 
including other parts of the chromatin modifying machinery, have well conserved orthologs 
(Hendrich & Tweedie, 2003). When expressed in Drosophila, hMECP2 associates with chromatin, 
can be modified by orthologs of known interacting proteins, and, like in mammals, is 
phosphorylated at serine 423 (Cukier et al., 2008), and causes specific defects in dendritic 
morphology (Vonhoff et al., 2012). 
Here, we use RNA-Seq with our Drosophila gain-of-function model to identify KIBRA as a 
novel gene activated by MECP2 required for dendritic impairments. Validation in mouse confirms 
that Mecp2 gain-of-function similarly causes dendritic defects in primary cortical neuron culture 
coupled with increased Kibra levels. Similarly, we find that loss of Mecp2 decreases Kibra levels 
in mouse hippocampus, cortex, and cerebellum, thus providing evidence for bidirectional 
regulation of Kibra by Mecp2 both in vitro and in vivo. We then employ the genetic power of 
Drosophila to demonstrate a functional consequence of increased kibra with hMECP2 
expression, finding that concomitant knockdown of kibra completely rescues the dendritic defects 
as caused by hMECP2 gain-of-function. Together, these data reveal memory associated KIBRA 
as a novel target of MECP2and provide evidence of a role for KIBRA in hMECP2 gain-of-function 
dendritic growth defects.  
 40 
Methods 
 
Animals 
Drosophila 
Drosophila melanogaster were reared in 68 ml vials on a standard yeast corn meal diet at 
25˚C and 60% humidity with a 12 hour light/dark cycle. UAS-hMECP2 and UAS-hR106W 
transgenic flies (Cukier et al., 2008; Vonhoff et al., 2012) were kindly provided by Dr. J Botas 
(Baylor College of Medicine, Houston, Texas). UAS-kibraRNAi on the X chromosome (Genevet, 
Wehr, Brain, Thompson, & Tapon, 2010) was obtained from the Vienna Drosophila Resource 
Center. UAS-Dcr2 (Bloomington stock 24650) was used to enhance the efficacy of the RNAi 
knockdown. Expression of UAS-Dcr2 alone has no effect on MN5 dendritic arborization 
(Hutchinson, Vonhoff, & Duch, 2014). UAS-kibra9 flies were a kind gift of Dr. Hugo Stocker 
(Institute of Molecular Systems Biology, Zurich, Switzerland). Additional UAS-kibra lines (UAS-
kibra18, H. Stocker and UAS-kibra-GFP, D.Pan) were used to verify the kibra overexpression 
phenotype in MN5 (data not shown). ELAV(C155)-GAL4 was used to drive expression of UAS-
transgenes pan-neuronally for RNA and/or protein analysis  (Lin & Goodman, 1994). For MN5 
dendritic analyses, we used C380-GAL4, UAS-mcd8-GFP;;Cha-GAL80, which selectively 
expresses GFP and other UAS-transgenes in a subset of motoneurons and other unidentified 
neurons (Sanyal, 2009). The Cha-GAL80 transgene inhibits expression in unidentified cholinergic 
sensory neurons and interneurons eliminating most known pre-synaptic connections. Thus, 
effects in MN5 are likely to result from cell autonomous signaling. For all Drosophila experiments, 
genetic controls were generated by crossing the GAL4 driver line to w1118 flies carrying the same 
genetic background as transgenic lines. 
Drosophila genotypes 
Figure 6 a: C380-GAL4, UAS-mcd8-GFP/Y;;Cha-GAL80 (control) 
6 b: C380-GAL4, UAS-mcd8-GFP/Y;;Cha-GAL80, UAS-hMECP2 
6 c: C380-GAL4, UAS-mcd8-GFP/Y;;Cha-GAL80, UAS-hR106W 
6 d-f: 
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ELAV(C155)-GAL4/Y;+; + (control) 
ELAV(C155)-GAL4/Y; ; UAS-hMECP2 
ELAV(C155)-GAL4/Y; + ; UAS-hR106W 
10 b: C380-GAL4, UAS-mcd8-GFP; ; Cha-GAL80 (control) 
10 c: C380-GAL4, UAS-mcd8-GFP; UAS-hMECP2;Cha-GAL80  
10 d: C380-GAL4, UAS-mcd8-GFP, UAS-kibraRNAi;UAS-dcr2, UAS-hMECP2 ; Cha-GAL80 
10 g: C380-GAL4, UAS-mcd8-GFP; UAS-dcr2, UAS-hMECP2; Cha-GAL80 
10 h: C380-GAL4, UAS-mcd8-GFP, UAS-kibraRNAi; UAS-dcr2 ;Cha-GAL80 
10i: C380-GAL4, UAS-mcd8-GFP; UAS-kibra9 ; Cha-GAL80 
12 a-b:  
ELAV(C155)-GAL4;+; + (control) 
ELAV(C155)-GAL4, UAS-kibraRNAi;+; + (control) 
 
Mice 
Mecp2 null mice (Stock ID 003890) and wild-type colony controls were obtained from The 
Jackson Laboratory (Bar Harbor, Maine) and were humanely euthanized for experiments at six-
seven weeks of age. The use and care of animals complied with institutional guidelines of the 
Transgenic Facility Mainz at the University Medical Center of the Johannes Gutenberg University 
Mainz. 
 
Cell Culture 
Postnatal day 0 (P0)-P1 mouse cortices were dissociated and transfected by 
Nucleofection (Lonza) or immediately plated onto polyornithine coated coverslips in 24 well plates 
in Neurobasal medium (Gibco) supplemented with 2% B27 (Gibco), and 1 mM L-glutamine. 
Mouse MECP2(e2)-GFP, MECP2(e2)-Myc/His, and N3-GFP plasmids were kindly provided by 
Dr. Vinodh Narayanan (Translational Genomics Research Institute, Phoenix, Arizona). 
MECP2(e2)-Myc/His was subcloned into pAM/CBA plasmids and used to generate chimeric 
AAV1/2 vectors as previously described for the control GFP vector (von Jonquieres et al., 2013)   
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RNA extraction and sequencing  
The brains of 30 individual male flies for each genotype were dissected on ice and flash 
frozen in liquid nitrogen. RNA was isolated using TRIzol© reagent (Life Technologies) and 
DNAse treated with the TURBO DNA-free™ Kit (Life Technologies). 50ng of pooled RNA 
quantified via Ribogreen (Invitrogen) was reversed transcribed and linearly amplified using 
Ovation RNA-Seq System V2 (NuGEN). 1ug of cDNA was fragmented using focused-
ultrasonication (Covaris) and libraries were subsequently prepared using Encore SP Rapid 
Library Systems (Nugen). Libraries were validated on a 2100 Bioanalyzer (Agilent Technologies) 
and quantified by qPCR with the KAPA Library Quantification Kit (KAPA Biosystems). Whole 
transcriptome paired-end data was generated with the HiSeq 2000 (Illumina) with samples 
multiplexed across three sequencing lanes. 150-180 million paired-end reads (90mers) were 
generated for each sample. Reads were aligned to D. melanogaster BDGP5 v67 with TopHat 
(version 2.0.2, bowtie version 0.12.7) using default parameters. Differential expression was 
analyzed using Cufflinks (version 0.9.3). The cutoff for determining significant differences 
between experimental groups (hMECP2 and hR106W) and control was a log scale fold difference 
of 0.2 and a false discovery rate (FDR) of less than 0.05 for the T-statistic corresponding to each 
comparison. 
Mouse array matches were determined by cross comparison with published array data 
from Mecp2 TG (over-expression mouse) and Mecp2 -/Y (null mouse) in hypothalamus (Chahrour 
et al., 2008), cerebellum (Ben-Shachar, Chahrour, Thaller, Shaw, & Zoghbi, 2009), striatum (null 
only)(Zhao, Goffin, Johnson, & Zhou, 2013), hippocampus (null only) (Baker et al., 2013) and 
amygdala (Mecp2 TG only) (Rodney C. Samaco et al., 2012). Human orthologs were obtained 
using the DRSC Integrative Ortholog Prediction Tool (Y. Hu et al., 2011), and only genes with 
scores ≥ 2.0 are listed.  
 
Quantitative Real-Time PCR 
Brain dissection and RNA extraction was completed as described above, with each 
sample consisting of five pooled male brains. cDNA was synthesized with Superscript III Reverse 
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Transcriptase (Life Technologies) and then treated with RNAse H (New England Biolabs). qRT-
PCR was performed with the Applied Biosystems 7900HT Fast PCR system and KAPA SYBR® 
FAST qPCR Kit Master Mix (KAPA Biosystems). Samples were run in triplicate and were 
normalized to αTub84B using the comparative Ct method. Samples with high variability within 
replicates (standard deviation greater than 1.5 cycles) were removed from analysis. Primers used 
were as follows: 
dkibra rev: 5’- CGTTTTCAATAGCCCAGGCG -3’ 
dkibra fwd: 5’- GCCCAAGTCAGTCACAAAACT -3’ 
dαTub84B fwd: 5’- CTTGTCGCGTGTGAAACACT -3’ 
dαTub84 rev: 5’- AGCAGTAGAGCTCCCAGCAG -3’ 
 
Western blotting 
For cell culture experiments, cells were harvested by scraping in cold lysis buffer (50mM 
Tris, 150 mM NaCl, 1mM EDTA, 1% Triton-X) containing protease and phosphatase inhibitors 
(Roche). Mouse brains were dissected and distributed directly into lysis buffer. Whole adult 
Drosophila brains (10/ sample) were dissected directly into cold lysis buffer. Proteins were 
separated by SDS-PAGE and transferred onto PVDF (Immobilion-P, Millipore) or nitrocellulose 
(Karl Roth) membranes. Membranes were blocked in 4% milk in TBST (0.05M Tris, 0.15 M NaCl, 
pH7.2, 0.1% (v/v) Tween20) for 30 minutes at room temperature and primary antibodies were 
applied overnight at 4˚C in blocking medium. Secondary antibodies were applied for one hour at 
room temperature. Band intensities were measured using ImageJ. Relative Kibra levels were 
normalized to the mean control value for each blot.  
 
Intracellular staining, image acquisition, and geometric reconstructions 
Adult Drosophila (1-2 days old) were dissected and dye filled with Neurobiotin solution 
(7% Neurobiotin (Vector Labs) and lysine fixable rhodamine-dextran 3000 (Life Technologies) in 
2 M potassium acetate) using sharp electrodes as described previously (Vonhoff & Duch, 2010; 
Vonhoff et al., 2012). After staining, ganglia were fixed in 4% paraformaldehyde (PFA) in PBS for 
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1 hour and washed in PBS. Tissue was permeated with 0.5% Triton X in PBS (6 X 30 minute 
washes), and primary antibodies and secondary antibodies were sequentially applied overnight at 
4˚C in 0.3% Triton X in PBS or pure PBS, respectively. Preparations were washed in PBS, 
progressively dehydrated in an ascending ethanol series, and mounted in methyl salicylate.  
For MN5 dendritic morphometric analysis, stacks of 0.3 µm optical sections (Drosophila whole 
mount) with 1024 X 1024 resolution were acquired on a Leica TCS SP8 laser-scanning confocal 
microscope with a 40X oil-immersion, 1.2 NA lens Image stacks were further processed with 
AMIRA 4.1.1 software (TGS) and custom AMIRA plug-ins were used for geometric dendrite 
reconstructions as previously published (Evers et al., 2005).  
Primary neuron cultures were fixed for 10 minutes in 4%PFA on coverslips in 24 well 
plates, and washed in PBS. Cells were permeated with 0.1% Triton X in PBS for two minutes, 
washed in PBS and incubated with primary antibodies in PBS for 1-2 hours at room temperature 
or overnight at 4˚C. Secondary antibodies were applied for 30-60 minutes and coverslips were 
mounted onto glass slides with Flouromount™ (Sigma-Aldrich). Images were acquired and 
processed as described above using a 20X oil-immersion (0.75 NA lens) to capture 1 µm optical 
sections. mMecp2 or control neurons were identified by positive GFP or myc labeling and 
neuronal identity was confirmed with B-III tubulin and NeuN co-labels. Positively transfected 
neurons were randomly selected and compared to the closest non-transfected neighbor within an 
individual coverslip to control for variability between cultures. At least ten cells per group were 
quantified and averaged for each transfection. 
 
Antibodies 
Western blot 
The mouse Kibra (raised in rabbit) antibody was a kind gift from Dr. Richard Huganir (The 
Johns Hopkins University School of Medicine, Baltimore, Maryland) and was used at 1:1,000 for 
Western blots (WB). GAPDH (rabbit; Bethyl Laboratories A300-641A) and MECP2 (rabbit; 
Thermo Scientific PA1-887) antibodies were both used at 1:5,000 for WB. The Drosophila kibra 
(raised in rabbit) antibody was a kind gift from Dr. Nicolas Tapon (London Research Institute, 
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London, UK) and used at 1:1,000 for WB. The anti-HSP90 (rabbit, Cell Signaling Technology 
#4874) was used as a loading control at 1:1,000 for WB. Anti-rabbit horseradish peroxidase 
(HRP) (Dianova #111-035-144) was used as a secondary antibody for all Western blots. 
 
Immunohistochemistry 
The following primary antibodies were used for cell culture and/or whole mount stainings:  
Β-III tubulin (chicken, abcam® ab107216) (1:1000), NeuN (rabbit, Merck Millipore #ABN78) 
(1:1000), GFP (mouse, Life Technologies A11121) (1:200), c-myc (mouse, Developmental 
Studies Hybridoma Bank 9E 10) (1:200), and MECP2 (mouse, abcam® ab50005). Cy3-
streptavidin (Jackson ImmunoResearch 016-160-084) (1:400) was used to visualize neurobiotin 
filled neurons. Additional secondary antibodies, including goat anti-mouse Alexa 488 (Life 
Technologies A-11001), donkey anti-mouse Alexa 647 (Jackson Immuno Research 715-605-
150), anti-rabbit Cy3 (Life Technologies A10042), and donkey anti-chicken Cy5 (Jackson 
ImmunoResearch 703-175-155) were applied at a concentration of 1:400.  
 
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism 6.0 or R Statistical Software. 
Non parametric statistics were used in the event a data set did not meet the assumptions of 
normality or equal variance between groups. Graphical representations were prepared using 
GraphPad Prism 6.07 and CorelDraw X7. Error bars are mean +/- SEM in all figures unless 
otherwise noted. 
 
Results  
 
Expression of hMECP2 in Drosophila causes MBD dependent changes in gene expression 
As in many neurodevelopmental diseases (Kaufmann & Moser, 2000; Kulkarni & 
Firestein, 2012), misregulation of MECP2 causes dendritic defects across many model systems, 
but the underlying mechanisms are poorly understood. In Drosophila, hMECP2 gain-of-function 
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dendritic defects are dependent on an intact MBD. Expression of a full-length hMECP2 causes a 
50% reduction in dendritic length and branches, while expression of a MBD point mutated human 
variant R106W (hR106W) has no effect on dendritic morphology (Vonhoff et al., 2012) (Figure 6 
a-c). To identify genes that specifically regulate dendrite development downstream of MECP2, we 
compared the transcriptomes of Drosophila brain with pan neuronal expression of hMECP2, 
hR106W, or without any MECP2 isoform (Figure 6 a-d). This differential RNA-Seq revealed 32 
genes that were potentially associated with dendritic defects because their expression was 
specifically altered with expression of hMECP2 but not hR106W (Figure 6 e). Consistent with 
array data from Mecp2 gain- and loss- of function mouse models (Ben-Shachar et al., 2009; 
Chahrour et al., 2008; Zhao et al., 2013), most genes were activated instead of repressed by 
hMECP2 (Figure 6 e). Of the 32 genes uniquely modified by hMECP2 and not hR106W, we 
narrowed our candidate genes to the 20 with known human orthologs, twelve of which have been 
identified to be regulated by MECP2 in the same direction in comparative gene expression 
analyses from MECP2 gain- or loss- of function mouse models (Baker et al., 2013; Ben-Shachar 
et al., 2009; Chahrour et al., 2008) (Appendix A). This provided a select subset of genes modified 
by MECP2 in both mouse and in Drosophila (Figure 6 g). Five of the twelve top candidate genes 
identified in the RNA-Seq screen have direct links to the Hippo signaling cascade, a pathway 
involved in regulation of dendritic morphology and cell size (Emoto, Parrish, Jan, & Jan, 2006; Yu 
et al., 2010) (Figure7 /Figure 6 g), two key cellular properties disrupted by MECP2 gain- and loss- 
of function (Jentarra et al., 2010).  
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Figure 6. Expression of hMECP2 in Drosophila CNS causes MBD dependent changes in 
gene expression. 
a-c. Previously reported dendritic phenotypes with targeted hMECP2 expression in the identified 
Drosophila motoneuron, MN5. Statistically significant reductions in total dendritic length are 
caused by targeted expression of hMECP2 (b), but not with targeted expression of hMECP2 with 
a point mutated non-functional MBD, hR106W (c). d. Schematic of RNA-Seq study design 
following no expression of hMECP2 and pan-neuronal expression of either hMECP2 or hR106W. 
e. Histogram comparing gene expression differences identified by RNA-Seq. f. qRT-PCR 
validation of dkibra upregulation with hMECP2 expression (n=7) versus control (n=8) (p < 0.05, t13 
= 2.56, Welch’s corrected two-tailed t-test). G. List of top nine candidate genes from RNA-Seq. 
Genes interacting with the Hippo signaling pathway are identified by red text. Hyp. = 
hypothalamus, cb.= cerebellum. Scale bars represent 10 µm 
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Figure 7. Top candidate genes identified by RNA-Seq screen converge onto the Hippo 
signaling pathway.  
Kibra activates Hippo signaling by interactions with mer and ex(Genevet et al., 2010). Activation 
of Hippo signaling prevents yki from entering the nucleus and turning on transcriptional targets, 
including kibra. All other candidate genes instead activate yki mediated transcription by either 
interacting directly with its transcriptional coactivator sd/TEAD2 (sox21b ortholog 
SOX12(Bhattaram et al., 2010)) or by inhibition higher up in the signaling cascade(Fan, Kim, & 
Gumbiner, 2013; Ribeiro et al.). β-arrestin (arr2) and PHGDH have not been shown to directly 
inhibit Hippo signaling, but they are known interactor of the inhibitors PP2A and aPKC (PKCzeta) 
(Beaulieu et al., 2005; Ma et al., 2013). LDHA (Impl3) has not been shown to act on Hippo 
signaling, but instead may be a transcriptional target (Xiang et al., 2015). 
 
 
KIBRA is bidirectionally regulated by MECP2 
Of these five genes, we selected KIBRA (HGNC Gene ID: WWC1) as a primary 
candidate gene for further analysis due to its position as an activator of this signaling cascade 
(Genevet et al., 2010) and used quantitative RT-PCR (qRT-PCR) to validate upregulation of 
Drosophila kibra (dkibra) with hMECP2 expression (Figure 6 f). KIBRA was additionally of high 
interest due to its association with learning and memory in humans and mouse models (Makuch 
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et al., 2011; Papassotiropoulos et al., 2006). While KIBRA has not been directly linked to 
intellectual disability or cognitive impairments, its postsynaptic localization and role in synaptic 
plasticity could provide a direct link to shared symptoms of RTT, MDS, and other autism spectrum 
disorders (Zoghbi & Bear, 2012). 
KIBRA was previously identified as one of hundreds of genes downregulated in the 
cerebellum of a mouse loss-of-function model (Mecp2tm1.1Bird or Mecp2-/y) (Guy et al., 2001)  
(Figure 6 g), but was not significantly altered on similar arrays of striatum, amygdala, 
hippocampus, or hypothalamus (Baker et al., 2013; Ben-Shachar et al., 2009; Chahrour et al., 
2008; R. C. Samaco et al., 2012; Zhao et al., 2013). However, of the thousands of genes 
differentially expressed with Mecp2 loss- and/or gain- of function, very few are consistently 
altered in all brain regions with previously published microarray data (Zhao et al., 2013). 
Furthermore, in mouse models, MECP2 dendritic impairments are variable across cell types, 
MECP2 mutation, and age, but have primarily been identified in pyramidal neurons of the cortex 
or hippocampus, regions with the highest basal Kibra expression (Allen Institute for Brain 
Science, 2015; Lein et al., 2007; Wang et al., 2013; Zhou et al., 2006). We therefore sought to 
verify the regulation of Kibra by mouse MECP2 (mMECP2) in cortex and hippocampus, where 
gain- or loss- of MECP2 function is associated with dendritic impairments (Armstrong, 2005; 
Cheng et al., 2014; Wang et al., 2013; Zhou et al., 2006). 
While reduced dendritic complexity has not been observed with mMecp2 gain-of-function 
in vivo, overexpression in primary neuron culture (Figure 8 a-b) and in slice culture consistently 
impairs dendritic growth (Cheng et al., 2014; Zhou et al., 2006). To test if Kibra is upregulated 
with mMecp2 gain-of-function in cultured neurons, we used both electroporation (0 DIV) and an 
adeno associated virus (AAV) (1 DIV) to overexpress mMecp2 in cortical neurons. Three days 
after mMecp2 delivery we found a 50% reduction in both total dendritic length and branching 
compared to controls (Figure 8 a-d; Figure 9 a-c). Immunoblots for mouse Kibra (mKibra) 
following AAV-mMecp2 transduction revealed a nearly two-fold increase in total mKibra protein 
levels (Figure 8 e), suggesting that MECP2 gain-of-function in mouse affects KIBRA similarly to 
hMECP2 gain-of-function in Drosophila. 
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We additionally assessed mKibra levels in Mecp2-/y mice to determine whether mMecp2 
loss-of-function also regulates Kibra in vivo in brain regions with associated dendritic 
impairments. We confirmed the decrease in mKibra in Mecp2-/y cerebella compared to within 
strain age matched controls, and additionally found decreased mKibra in both cortex and 
hippocampus (Figure 8 f-g). Together, these results confirm that MECP2 bidirectionally regulates 
KIBRA in brain regions of model systems where it also impairs dendrite development. 
 
 
Figure 8. MECP2 disrupts dendritic function and bidirectionally regulates Kibra levels in 
mouse brain. 
a,b. Representative traces of transfected primary cortical neurons from each replicate experiment 
(n=5). c,d. Quantification of total dendritic length (TDL) and number of branches following 
mMECP2 overexpression (** p<0.005 Tukey post-hoc following two-way ANOVA, F1,16 = 35.94, p 
< 0.0001). Error bars are mean +/- SEM for replicate experiments. e. Representative Western blot 
and quantification of relative mKibra levels following AAV mediated overexpression of mMecp2 in 
primary cortical neurons (*p < 0.05, U= 4, Mann-Whitney U-test, n = 6 independent assays per 
group). f,g. Representative Western blots of mKibra from hippocampus (hipp.), cerebellum (cb.), 
and cortex (ctx) of Mecp2-/y mice and Mecp2+/y controls (**p < 0.01, *p < 0.05 Tukey post-hoc 
following two-way ANOVA, F1,18 = 62.28, p < 0.0001, n = 4 per genotype). Scale bar represents 
50 µm. 
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Figure 9. Overexpression of mMecp2 using AAV causes the same dendritic phenotype as 
electroporation method 
a. Representative image of AAV-mMecp2-myc transduced neuron in at 4DIV in culture shows 
localized nuclear expression (aii). b. Quantification of total dendritic length (TDL) and number of 
branches following AAV transduction (*p < 0.05, Bonferroni t-test after 2-way ANOVA, F1,36 = 
13.09, p < 0.001, n = 10 cells per group). C. Representative Western blot showing mMecp2 
expression following in primary cortical neurons following AAV-mMecp2-myc transduction. Scale 
bar represents 20µm. 
 
 
 
 
Increased kibra is necessary, but not sufficient, to cause dendritic defects 
 To test whether manipulation of KIBRA could work as a useful tool to rescue MECP2 
gain-of-function dendritic growth impairments, we returned to the Drosophila model. We 
expressed hMECP2 in an identified motoneuron (MN5), which displays a stereotyped and well 
described dendritic morphology, thus allowing for quantitative in vivo dendritic structure analysis 
following genetic interaction experiments (Duch et al., 2008; Hutchinson et al., 2014; Vonhoff & 
Duch, 2010; Vonhoff, Kuehn, Blumenstock, Sanyal, & Duch, 2013; Vonhoff et al., 2012). As 
previously reported, expression of full length hMECP2 in MN5 reduced total dendritic length and 
the number of dendritic branches by 50% compared to controls (Figure 10 b-c). RNAi mediated 
knockdown of dKibra with hMECP2 expression (dkibraRNAi;hMECP2), however, completely 
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rescued total dendritic length to that of controls (Figure 10 d-e, Figure 12 a-b). By contrast, the 
number of branches was only partially rescued (Figure 9 f). Sholl analysis revealed that this was 
due to fewer branches closer to the primary neurite (between 5-20µm) in dkibraRNAi;hMECP2 
flies, an effect that was also observed with dkibraRNAi alone (Figure 11 a-b). Despite subtle 
changes in branch patterning, dkibraRNAi alone had no significant effect on total dendritic length 
or branch number (Figure 10 h). Moreover, while overexpression of dkibra alone (kibra9, Figure 
10 i) also caused subtle changes in branch patterning (Figure 11 a-b), it had no effect on total 
dendritic length or branch number. This suggests that the increase in dkibra with hMECP2 
expression is necessary to disrupt dendritic morphology, but altered dkibra levels alone are not 
sufficient to cause defects. This finding was verified with three independent UAS-dkibra lines 
(data not shown) and indicates that the major effects of kibra on dendritic growth must therefore 
be dependent on additional hMECP2 gain-of-function induced changes (see discussion).  
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Figure 10. Knockdown of kibra rescues hMECP2 induced dendritic defects in Drosophila 
MN5. 
a. Schematic of Drosophila CNS and dorsal longitudinal flight depressor muscle innervation by 
MNs 1-5. b-d, g-i. Representative geometric reconstructions of MN5 dendritic trees superimposed 
onto representative projection views for each labeled group. ci-ii, di-ii. hMECP2 (magenta) is 
expressed and localizes to the nucleus of MN5 (white arrows) with (di-ii) and without (ci-ii) 
knockdown of dkibra. e,f. Quantification of total dendritic length (e) and number of branches (f) for 
all experimental and control genotypes (*** p < 0.0001, * p < 0.05 Tukey post-hoc following two-
way ANOVA, F5,46 = 56.30, p <0.0001, n = 3-7 cells per group). All constructs were expressed 
using the C380-GAL4, cha-GAL80 driver line (see Online Methods for complete list of 
genotypes). Scale bars represent 10µm.  
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Figure 11. Sholl analysis of Drosophila MN5 dendritic morphology with targeted genetic 
manipulations. 
a. Quantification of the number of intersections or per 10µm Sholl sphere (* p < 0.05, Bonferroni t-
test after two-way ANOVA, F5,192 = 38.65, p < 0.0001, n = 3-7 cells per group). b. Quantification of 
total dendritic length per Sholl sphere (* p < 0.05, Bonferroni t-test after two-way ANOVA, F5,192 = 
31.35, p < 0.001, n = 3-7 cells per group). The entire primary neurite of MN5 was defined as the 
tree origin for Sholl analysis. 
 
 
 
 
 
 
 
 
 
 
Figure 12. kibraRNAi moderately decreases dkibra levels in Drosophila brain. 
a. Representative Western blot for dkibra following pan neuronal kibra knockdown. b. 
Quantification of Western blot analysis (* p < 0.05 unpaired t-test, t23 = 2.59, n = 12-13 per group. 
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Discussion 
 
Our study identifies KIBRA as a novel player in MECP2 related dendritic pathology. While 
genetic and behavioral proof of principle for using Drosophila to study hMECP2 gain-of-function 
has been well established (Cukier et al., 2008; Vonhoff et al., 2012), we now utilize this system to 
identify new MECP2 targets. We then focus on KIBRA as one such target, confirm it in the mouse 
model with endogenous MECP2, and employ the genetic power of Drosophila to rescue MECP2 
induced cellular defects by concomitant reduction of KIBRA. 
In addition to KIBRA, we have identified eleven genes modified by MECP2 in both 
Drosophila and in mouse models (see Figure 6g) that may be involved in MECP2 dependent 
dendritic defects. Interestingly, four of these genes have direct links to the Hippo kinase signaling 
network (Figure 7), which is known to regulate dendrite development (K. Emoto, 2011; Ultanir et 
al., 2012; Yang et al., 2011) but has not previously been associated with MECP2 induced 
neurodevelopmental defects.  Our data indicate a potential role of the Hippo signaling network in 
Rett/MDS pathology. Disruption of this pathway has been associated with both cancers and other 
neurological diseases, including amyotrophic lateral sclerosis, Alzheimer’s disease, and 
schizophrenia (Lee et al., 2013; Melka, Castellani, O’Reilly, & Singh, 2015; Orcholski, Zhang, & 
Bredesen, 2011; Plouffe, Hong, & Guan, 2015). However, additional work will be needed to 
determine whether MECP2 disruption of Hippo signaling is relevant to the cellular and behavioral 
phenotypes of Rett and MDS. 
The mechanism by which hMECP2 acts to modify expression of kibra and the other 
genes identified through the RNA-Seq screen remains unknown. Because the Drosophila 
genome is sparsely methylated (Capuano et al., 2014), it is unlikely that hMECP2 acts by binding 
to 5’mCpG and repressing transcription (Nan et al., 1997). Accordingly, all twelve of the genes 
modified in both Drosophila and mouse models are activated by MECP2 in both model systems. 
Overall, we found far more genes activated by hMECP2 in Drosophila CNS than repressed. This 
is consistent with array data from mouse hypothalamus and cerebellum that suggests MECP2 
may be more of an activator than a repressor (Chahrour et al., 2008). How MECP2 acts to 
activate genes is unclear in any system, but in mouse it has been found to associate with the 
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major transcriptional activator CREB1 in the promoter region of activated genes (Chahrour et al., 
2008). In one such example, the binding of MECP2 and CREB1 to the promoter region of 
transcriptional target Glut3 is dependent on 5’mCpG binding, but MECP2 still activates Glut3 
expression in the absence of DNA methylation (Chen et al., 2013). Thus, it is possible that 
hMECP2 can activate many of the same genes in Drosophila without direct 5’mCpG binding. In 
addition, hMECP2 may act in the fly by one of its many identified functions not dependent on 
DNA methylation, such as RNA splicing or suppression of microRNA processing, the latter of 
which has a demonstrated role in MECP2 dendritic growth defects (Cheng et al., 2014; Young et 
al., 2006). 
The primary motivation to screen for MECP2 targets is to identify potential future 
treatment targets to ameliorate cellular defects as induced by mis-regulation of MECP2.  We 
show here that, at least in Drosophila, knockdown of dkibra with hMECP2 expression can rescue 
the severe dendritic impairments observed with hMECP2 alone, but manipulation of dkibra alone 
is not sufficient to cause similar impairments. This is consistent with the fact that both MECP2 
gain- and loss- of function impair dendritic growth but have opposing effects on KIBRA levels. 
The role of KIBRA in Hippo signaling could potentially provide an explanation on how this could 
occur. In Drosophila it is known that dkibra activates the Hippo signaling pathway through 
interactions with Mer and Ex, which ultimately inhibits the activation of the transcription factor Yki 
(Yu et al., 2010). Kibra itself is also a Yki target, and therefore can regulate its own expression 
through a Hippo mediated negative feedback loop (Genevet et al., 2010). This may also provide 
an explanation as to how we found a large difference in mKibra at the protein level in 
hippocampus with mMecp2 loss-of-function, while mkibra transcript levels have previously been 
reported unchanged at similar ages (Baker et al., 2013). Furthermore, overexpression and 
knockdown manipulations may have only subtle effects on overall KIBRA levels, while the 
activation and/or inhibition of Hippo signaling via KIBRA and additional regulators (see Figure 7) 
may result in more dramatic effects. Accordingly, while the Drosophila kibraRNAi line used for 
kibra knockdown produced robust eye and wing growth phenotypes in an RNAi screen strong 
enough to identify a novel function of KIBRA (Genevet et al., 2010), our Western blot analysis 
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from brains collected following pan-neuronal dkibra knockdown revealed a significant but very 
modest 30 percent decrease in total dkibra levels (See Figure 12). Considering that this subtle 
reduction in dkibra leads to a near complete reversal of the hMECP2 dendritic phenotype but has 
minimal impact on dendritic arborization alone, targeting KIBRA and/or Hippo signaling could be 
an exciting option for the development of potential future therapeutic strategies.  
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CHAPTER 4 
MECP2 C-TERMINAL TRUNCATING MUTATIONS CAUSE NEURONAL APOPTOSIS 
By Alison Williams, Vera Mehler, Christina Mueller, Fernando Vonhoff, 
Robin White & Carsten Duch 
Abstract 
 
Methyl-CpG binding protein 2 (MeCP2) is a widely abundant, multifunctional protein most highly 
expressed in post-mitotic neurons. MECP2 mutations causing Rett syndrome and related 
neurodevelopmental disorders have been identified along the entire MECP2 locus, but symptoms 
vary depending on mutation type and location. C-terminal mutations are prevalent, but little is 
known about the function of the MECP2 C-terminus. We employ the genetic power of Drosophila 
to provide evidence that R294X, a human MECP2 E2 mutant allele causing premature truncation 
of the C-terminal domains, promotes apoptosis of identified neurons in vivo. We confirm this 
novel finding in cultured human embryonic kidney cells and then use Drosophila to map the 
region critical for neuronal apoptosis to a small section at the end of the C-terminal domain. In 
vitro studies in mammalian systems previously indicated a role of the MECP2 E2 isoform in 
apoptosis, which is facilitated by phosphorylation at serine 80 (S80) and decreased by 
interactions with the forkhead protein FoxG1. We confirm the roles of S80 phosphorylation and 
forkhead domain transcription factors in affecting MECP2 induced apoptosis in Drosophila in vivo, 
thus indicating mechanistic conservation between flies and mammalian cells. Our data, however, 
indicate that the apoptotic potential of MECP2 is most severely enhanced by C-terminal 
truncation mutations. Paradoxically, disease prognosis of C-terminal truncations is less severe 
than for other MECP2 mutations. We propose that increased neuronal death caused by C-
terminal MECP2 truncations during early brain development may lead to a higher proportion of 
neurons with the mutated X-chromosome inactivated, and therefore improve symptomatic 
severity. 
 
Introduction  
 
Methyl-CpG binding protein 2 (MECP2) is a ubiquitous and multifunctional protein most 
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highly expressed in mature neurons (Kishi & Macklis, 2004). Both MECP2 loss- and gain- of 
function cause neurodevelopmental disorders (Rett Syndrome or MECP2 Duplication Syndrome, 
respectively) characterized by severe cognitive, language, and motor impairments. While 
mutations causing Rett Syndrome and related disorders have been identified across the entire 
length of the MECP2 locus (Christodoulou, Grimm, Maher, & Bennetts, 2003), the severity and 
range of symptoms varies between patients depending on the location and nature of the MECP2 
mutation (del Gaudio et al., 2006; Jeffrey L. Neul et al., 2014; Robertson et al., 2006; Schanen et 
al., 2004). Accordingly, analysis of the various molecular and cellular functions of different 
domains of MECP2 will be a useful basis to better understand MECP2 related pathophysiology.   
MECP2 is traditionally known as a transcriptional repressor that binds to methylated CpG 
regions via the methyl binding domain (MBD) and silences local gene expression via the 
transcription domain (TRD) (Jones et al., 1998).  However, MECP2 has additionally been shown 
to activate transcription in mouse models (Chahrour et al., 2008) and can form complexes with 
RNA binding proteins (Young et al., 2006). MECP2 can also bind non-methylated DNA (Ghosh et 
al., 2010; Hansen et al., 2010) and such interactions may influence local chromatin structure 
(Ghosh et al., 2010).  
On the cellular level, MECP2 misregulation negatively impacts dendritic structure as 
shown in patients (Armstrong, 2005), in vivo in mouse (Chen, Akbarian, Tudor, & Jaenisch, 2001; 
Jentarra et al., 2010; Stuss, Boyd, Levin, & Delaney, 2012; Wang et al., 2013) Xenopus (Marshak 
et al., 2012), and Drosophila (Vonhoff et al., 2012) models, and in primary neuron and slice 
cultures (Cheng et al., 2014; Zhou et al., 2006). Additionally, overexpression of MECP2, 
specifically the E2 isoform, contributes to apoptosis in cell culture (Bracaglia et al., 2009; Dastidar 
et al., 2012). In cerebellar granule neurons, MECP2 induced apoptosis is inhibited by elevated 
levels of the forkhead protein FoxG1, mutations of which also cause Rett related diseases 
(Dastidar et al., 2012). However, the exact molecular mechanisms of MECP2 induced apoptosis 
and the relationship to MECP2 related pathophysiology are not well understood.  
Here, we utilize a Drosophila MECP2 gain-of-function model to investigate the role of the 
MECP2 in neuronal cell death in vivo. While there is no Drosophila MECP2 ortholog, multiple 
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MECP2 interactors and most components of the chromatin machinery are conserved in the fly. 
When expressed in Drosophila, human MECP2 will associate with chromatin, modify 
transcription, and become phosphorylated at the same sites as in mammals (Cukier et al., 2008). 
Furthermore, expressing human MECP2 in the fly has helped identify novel MECP2 interactors 
that have been subsequently validated in mouse model systems (Cukier et al., 2008).  
 Using this model, we provide evidence that MECP2 promotes apoptosis in vivo and 
identify a role for the C-terminus and serine 80 phosphorylation in mediating this effect. We show 
that MECP2 gain-of-function apoptosis in Drosophila is likely acting via the same cellular 
pathways as in mammalian cells, and have established a behavioral assay that can be used for 
high-throughput screening to identify additional molecular players in MECP2 induced neuronal 
apoptosis. Furthermore, we have identified a new functional consequence of MECP2 C-terminal 
truncating Rett Syndrome mutations and hypothesize that apoptosis caused by MECP2 
truncation during early brain development may ultimately lead to reduced clinical severity 
observed in patients carrying such mutations (Bebbington et al., 2008; Cuddapah et al., 2014; J. 
L. Neul et al., 2008; Schanen et al., 2004) by leaving a high proportion of healthy neurons with 
the mutation carrying X-chromosome inactivated. 
 
Methods 
Drosophila stocks 
Drosophila melanogaster were reared in 68 ml vials on a standard yeast corn meal diet at 
25˚C and 60% humidity with a 12 hour light/dark cycle. All previously generated and new MECP2 
variants were derived from MECP2-E2 isoform cDNA. Previously generated p-element insertion 
lines UAS-MECP2FL and UAS-R294X (Cukier et al., 2008) were kindly provided by Dr. J Botas 
(Baylor College of Medicine, Houston, Texas). CD8:PARP::VENUS flies were kindly provided by 
Dr. J. Truman (HHMI Janelia Research Institute, Ashburn, Virginia). Microinjection of all 
constructed pUASTattB vectors into embryos carrying the attP2 landing site (BDSC Stock # 
8622) was done by Bestgene (www.thebestgene.com). For cellular analyses, we used the C380-
GAL4 driver which selectively expresses UAS-transgenes in a subset of motoneurons and other 
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unidentified neurons (Boerner & Duch, 2010; Sanyal, 2009). For cylinder drop experiments, the 
Cha-GAL80 transgene was included to inhibit expression in unidentified cholinergic sensory 
neurons and interneurons thus eliminating most known pre-synaptic connections (Sanyal, 2009). 
ELAV(C155)-GAL4 was used to drive pan neuronal expression of UAS-transgenes for protein 
analysis  (Lin & Goodman, 1994). GAL-4 driver lines were crossed to W1118 flies to generate 
genetic non-MECP2 carrying controls for all experiments. 
 
Drosophila genotypes 
Figure 1b: C380-GAL4, UAS-mcd8-GFP/X;;Cha-GAL80/+ (control) 
1c: C380-GAL4/X;;UAS-MECP2FL/UAS-mcd8-hPARP:VENUS 
1d: C380-GAL4/X;;UAS-R294X/UAS-mcd8-hPARP:VENUS 
1e: C380-GAL4/X;UAS-MECP2FL/+;UAS-R294X/UAS-mcd8-hPARP:VENUS 
Figure 3a: C380-GAL4/X;;UAS-R294X/UAS-mcd8-hPARP:VENUS 
b: C380-GAL4/X;;UAS-V312X/UAS-mcd8-hPARP:VENUS 
c: C380-GAL4/X;;UAS-K431X/UAS-mcd8-hPARP:VENUS 
d. C380-GAL4/X;;UAS-V481X/UAS-mcd8-hPARP:VENUS 
e. C380-GAL4/X;;UAS-MECP2FL/UAS-mcd8-hPARP:VENUS 
Figure4a: C380-GAL4/X;;UAS-MECP2FL/UAS-mcd8-hPARP:VENUS 
4b: C380-GAL4/X;;UAS-MECP2FLS80E/UAS-mcd8-hPARP:VENUS 
4c: C380-GAL4/X;;UAS-R294XS80A/UAS-mcd8-hPARP:VENUS 
Figure 5a: C380-GAL4/X;;UAS-R294X/UAS-mcd8-hPARP:VENUS 
5b: C380-GAL4/X;UAS-slp1;UAS-R294X/UAS-mcd8-hPARP:VENUS 
5d, e: 
Control: C380-GAL4, UAS-mcd8GFP/Y;;cha-GAL80/+ 
MECP2FL: C380-GAL4, UAS-mcd8GFP/Y;;UAS-MECP2FL/cha-GAL80 
R294X: C380-GAL4, UAS-mcd8GFP/Y;;UAS-R294X/cha-GAL80 
Slp1;R294X: : C380-GAL4, UAS-mcd8GFP/Y;UAS-slp1/+;UAS-R294X/cha-GAL80 
Figure S1 (all): C380-GAL4/X;;UAS-R294X/UAS-mcd8-hPARP:VENUS 
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Figure S2:  
C380-GAL4/X;;UAS-MECP2FL/UAS-mcd8-hPARP:VENUS 
C380-GAL4/X;;UAS-V481X/UAS-mcd8-hPARP:VENUS 
C380-GAL4/X;;UAS-K431X/UAS-mcd8-hPARP:VENUS 
C380-GAL4/X;;UAS-V312X/UAS-mcd8-hPARP:VENUS 
C380-GAL4/X;;UAS-R294X/UAS-mcd8-hPARP:VENUS 
S2b: ELAV(C155)-GAL4/Y;;UAS-MECP2FL/+ 
ELAV(C155)-GAL4/Y;;UAS-K431X/+ 
 
Molecular Biology 
The pUASTattB vector was kindly provided by the lab of Dr. K. Basler (Institute of 
Molecular Life Sciences, Zurich, Switzerland). Human MECP2-E2 cDNA was obtained from the 
DNASU Plasmid Repository at Arizona State University (Clone ID HsCD00434196). 
MECP2FLS80E and S80A plasmids were previously generated (Bracaglia et al., 2009) and kindly 
provided by Dr. C. Kilstrup-Nielsen (University of Insubria, Busto Arsizio, Italy). To generate new 
full-length and truncated MECP2 constructs, PCR amplified sequences were cloned into 
pUASTattB using EcoRI and NotI (New England Biolabs). Truncated constructs were generated 
by inserting a TGA stop codon prior to the 3’ NotI site. The following primers were used to amplify 
and generate new pUASTattB constructs: 
FWD (all constructs): 5’ GAATTCCCACCATGGTAGCTGGGAT 3’ 
MECP2FL/MECP2FLS80E REV:  
5’ GAGGAGCGGCCGCTCAGCTAACTCTCTCGGTCACGG 3’ 
R294X/R294XS80A REV: 5’ GAGGAGCGGCCGCTCAGATAGAAGACTCCTTCACGGCTT 3’ 
V312X REV: 5’ GAGGAGCGGCCGCTCACGTCTCCCGGGTCTTGC 3’ 
L431X REV: 5’ GAGGAGCGGCCGCTCAGGGGCAGCCGTCG 3’ 
V481X REV: 5’ GAGGAGCGGCCGCTCAGGGCGTCCGGCTGTCCAC 3’ 
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For transfection and expression in cell culture, PCR amplified sequences were cloned into 
pN3GFP plasmid (See Chapter 3) at the EcoRI and BamI sites using the following reverse 
primers: 
FWD: 5’ GAATTCCCACCATGGTAGCTGGGAT 3’ 
MECP2FL REV: 5’ GAGGAGGATCCGCTAACTCTCTCGGTCACGG 3’ 
R294X REV:  5‘ GAGGAGGATCCGATAGAAGACTCCTTCACGGCTT 3‘ 
 
Cell culture  
HEK293T cells were cultured in DMEM+Glutamax (Life technologies) supplemented with 
10% fetal calf serum and 10000U Penicillin/Streptomycin (Life technologies) at 37°C and 5%CO2. 
Per glass coverslip, 30000 cells were plated and transfected using 1µl Fugene HD (Promega) 
with 0.75µg Plasmid DNA according to manufacturer’s protocol. Some coverslips were treated 
with 2µM staurosporine for 18 h to serve as a positive control for apoptotic morphology.  
 
Western blotting 
For cell culture experiments, cells were harvested by scraping in cold lysis buffer (50mM 
Tris, 150 mM NaCl, 1mM EDTA, 1% Triton-X) containing cOmplete EDTA-free protease and 
PhoStop phosphatase inhibitors (Roche). Whole adult Drosophila heads (10 per sample) were 
dissected directly into cold lysis buffer. Proteins were separated by SDS-PAGE and transferred 
onto nitrocellulose (Karl Roth) membranes. Membranes were blocked in 4% milk in TBST (0.05M 
Tris, 0.15 M NaCl, pH7.2, 0.1% (v/v) Tween20) for 30 minutes at room temperature and primary 
antibodies were applied overnight at 4˚C in blocking medium. GAPDH (rabbit; Bethyl Laboratories 
A300-641A) and MECP2 (rabbit; Thermo Scientific PA1-887) antibodies were both used at 
1:5,000 for Western blot. Anti-HSP90 (rabbit, Cell Signaling Technology #4874) was used at 
1:1,000 for WB. Anti-rabbit horseradish peroxidase (Dianova #111-035-144, 1:10,000) was 
applied for one hour at room temperature. 
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Immunohistochemistry 
Drosophila were dissected and ganglia were fixed in 4% paraformaldehyde (PFA) in PBS 
for 1 hour and washed in PBS (0.1M). Tissue was permeated with 0.5% Triton X in PBS (6 X 30 
minute washes), and primary antibodies and secondary antibodies were applied overnight at 4˚C 
in 0.3% Triton X in PBS or in PBS, respectively. Preparations were washed in PBS, progressively 
dehydrated in an ascending ethanol series, and mounted in methyl salicylate. Cell cultures were 
fixed for 15 minutes in 4% PFA in PBS on coverslips and washed in PBS. Cells were permeated 
with 0.1% Triton X in PBS for two minutes, washed in PBS and incubated with primary antibodies 
in PBS for 1-2 hours at room temperature or overnight at 4˚C. Secondary antibodies were applied 
for 30-60 minutes and coverslips were mounted onto glass slides with Fluoromount™ (Sigma-
Aldrich). For propidium iodide staining (C. Duch, Bayline, & Levine, 2000), cells were first treated 
with 0.1 mg/ml RNase (Sigma-Aldrich) for 15 minutes at 37˚C followed by 50 µl of a 500 µM 
propidium iodide stock solution (Sigma-Aldrich) for 30 minutes at room temperature. 
Stacks of 0.5 µm (Drosophila whole mount) or 1.0 µm optical sections with 1024 X 1024 
resolution were acquired on a Leica TCS SP8 laser-scanning confocal microscope (LSCM) with a 
20X (0.75 NA) or 40X (1.2 NA) oil-immersion lens.  
 
Antibodies 
The following primary antibodies were used for cell culture and/or whole mount stainings: 
Rabbit anti-cleaved PARP Ab2317 (1:500, Abcam), chicken anti-GFP A10262 (1:400, Life 
Technologies), and mouse anti-MECP2 ab55538 (1:400, Abcam). Rabbit cleaved caspase-3 
ASP175 (1:100, Cell Signaling Technology) was used to confirm apoptotic nuclei (data not 
shown). All secondary antibodies, including goat anti-chicken Alexa 488 (Life Technologies A-
11039), donkey anti-Mouse Alexa 568 (Life Technologies A10037), donkey anti-mouse Alexa 647 
(Jackson Immuno Research 715-605-150), and donkey anti-rabbit Cy5 (Jackson 
ImmunoResearch 711-175-152) were applied at a concentration of 1:400. 
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Image analysis 
For HEK293T cell experiments, transfection was confirmed by GFP 
immunohistochemistry and cell viability was assessed by propidium iodide staining, with 
condensed or fragmented nuclei counted as apoptotic, as described by others (Dastidar et al., 
2012; Dastidar et al., 2011; Koulich, Nguyen, Johnson, Giardina, & D'Mello, 2001). Each 
transfection experiment was replicated six times, with at least 400 cells counted per transfection. 
For quantitative analysis of cPARP immunoreactivity in MN5, all preparations analyzed were 
subjected simultaneously to the identical immunohistochemistry procedure by processing them in 
the same dish, and images were acquired with the exact same LSCM parameters within one 
imaging session. To analyze images, the mean grey value of each MN5 somata was calculated 
for the cPARP channel using Image J. This value was normalized to the respective grey value 
measured from the GFP channel to control for potential differences in reporter availability. 
 
Flight Assay 
The “cylinder drop assay” was adapted with minor modifications from a previously 
described flight test (Benzer, 1973). Briefly, male flies were collected by suctioning at 24 hours 
post-eclosion and distributed into 0.5ml Eppendorf tubes with a small filter paper containing 5µl a 
10% sucrose solution at the bottom. After a two hour acclimation period, flies were injected 
individually into a 33.3cm glass cylinder using a custom made spring-loaded releasing device. 
The landing height of each fly was recorded, and any non-flyers were collected at the bottom of 
the cylinder. 
 
Statistical Analysis 
FoxG1/slp1 sequence alignment was conducted using Jalview Version 2.9 (Waterhouse, 
Procter, Martin, Clamp, & Barton, 2009). Statistical analyses were conducted using GraphPad 
Prism 6.0 or R Statistical Software. Non parametric statistics were used in the event a data set 
did not meet the assumptions of normality or equal variance between groups. Graphical 
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representations were prepared using GraphPad Prism 6.07 and CorelDraw X7. Error bars are 
mean +/- SEM in all figures unless otherwise noted. 
 
Results 
 
R294X gain-of-function causes apoptosis in MN5 
Mutations causing Rett Syndrome have been identified in all annotated functional 
domains of MECP2 but occur most abundantly in the two best characterized domains, the MBD 
(AA 78-162) and the TRD (AA 207-310) (Bedogni et al., 2014) (Figure 13 a). In a mouse model of 
MECP2 duplication syndrome, both the MBD and TRD are required for the behavioral 
consequences of MECP2 gain-of-function (Heckman, Chahrour, & Zoghbi, 2014). We have 
previously shown that the dendritic phenotype observed with human MECP2 expression in an 
identified Drosophila neuron, motoneuron 5 (MN5), is also dependent on an intact MBD (Vonhoff 
et al., 2012). MN5 is a monopolar flight motoneuron that innervates the major wing depressor 
muscle (Ikeda & Koenig, 1988). MN5 is well suited for analyzing genetic interactions and cellular 
consequences of MECP2 gain-of-function alleles because it is (i) individually identifiable, (ii) 
displays a stereotyped and well quantified morphology (Vonhoff & Duch, 2010), (iii) is 
physiologically well described (Duch et al., 2008; Ryglewski & Duch, 2009; Ryglewski, Kilo, & 
Duch, 2014; Ryglewski et al., 2012), and (iv) can be addressed by targeted genetic manipulation 
(Hutchinson et al., 2014; Vonhoff et al., 2013; Vonhoff et al., 2012) with the binary GAL4-UAS 
expression system (Brand & Perrimon, 1993).  We use the C380-Gal4; Cha-Gal80 driver line to 
heterologously express human MECP2 in MN5 labeled with GFP (Duch et al., 2008; Hutchinson 
et al., 2014; Vonhoff & Duch, 2010; Vonhoff et al., 2013; Vonhoff et al., 2012). C380-GAL4 
expresses in about 30 neurons per hemisegment of the Drosophila ventral nerve cord (VNC), 
most of which are glutamatergic motoneurons including MN5 (Figure 13b) (Boerner & Duch, 
2010). Both left and right MN5 can easily be visualized in the mesothoracic neuromere by GFP 
expression (Figure 13b). 
Using this model, we sought to examine the role of the TRD with gain-of-function in 
Drosophila by expressing the truncated human MECP2 allele R294X, which accounts for about 
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5% of typical Rett patients (Dragich, Houwink-Manville, & Schanen, 2000), in MN5. To our 
surprise, the large, readily identifiable somata of MN on both sides of the mesothoracic 
neuromere (Figure 13b) were missing in most adult flies expressing R294X, a phenomenon not 
observed with expression of full length MECP2 (MECP2FL) or MBD mutated MECP2 (Vonhoff et 
al., 2012). To determine whether this was due to a developmental defect or post mitotic cell death 
we examined the ventral nerve cords at various pupal stages and always found MN5 somata on 
both sides of the VNC up to pupal stage P8 (about 50% of pupal life) and occasionally up to pupal 
stage 15 (Figure 14). Quantification at pupal stage P15 (0-15 hours prior to eclosion) showed that 
MN5 somata were present on both sides of the VNC in 100% of all control and MECP2FL 
expressing flies (Figure 13b-c). Following expression of R294X, both MN5 somata were present 
in only 16% of flies. One MN5 was present in 32% of preparations with one MN5, and both MN5 
somata were missing in the remaining 52% of preparations (Figure 13d). Therefore, following 
expression of R294X, MN5 differentiates during the first half of pupal life but dies during the 
second half.   
To establish whether the cell death occurred due to caspase mediated apoptosis or 
another form of neuronal toxicity, we co-expressed a genetically encoded caspase activity 
reporter CD8::hPARP::Venus (Williams, Kondo, Krzyzanowska, Hiromi, & Truman, 2006). With 
this reporter, activated Drosophila caspases will cleave the human PARP protein tethered to a 
membrane bound Venus tag, and caspase activity can be visualized by using an antibody specific 
to human cleaved PARP (cPARP). Following expression of R294X we detected caspase activity 
throughout residual degenerating arborizations of MN5 even after the somata had already 
disappeared at early adult stages (Figure 13d). By contrast, following expression of MECP2FL we 
could not detect significant levels of caspase activity in the somata or any arbors of MN5 (Figure. 
13c). C380-GAL4 drives expression of UAS-transgenes from early pupal stage P5 through 
adulthood (Vonhoff et al., 2013). During pupal life, caspase activity could first be detected with 
R294X expression in MN5 at stage P10 and increased at later pupal stages (Figure 14) indicating 
the effects of R294X were not immediate upon onset of transgene expression.  
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Between P10 and eclosion, cell death patterning and timing is variable between flies, but 
no intact cell bodies were found beyond one day post-eclosion in over 30 flies analyzed. We 
further determined that the effects of R294X exert a dominant negative effect over full length, 
intact MECP2, as concomitant expression of R294X with MECP2FL led to high caspase activity 
and cell death in MN5 in a similar temporal pattern as R294X alone (Figure 13e).  
 
 
Figure 13. R294X truncation causes caspase mediated apoptosis in Drosophila MN5. 
a. Structural schematics of the MECP2FL and R294X alleles used for experiments. Only the 
MECP2 E2 isoform is shown and was used for experiments. b. Schematic of Drosophila central 
nervous system showing localization of motoneuron 5 (MN5) within the adult ventral nerve cord 
(VNC). GFP labeling with the C380-GAL4 motoneuron driver line is shown overlaying the VNC, 
and confocal projections views of GFP labeled MN5 somata are shown as selective enlargements 
at right. c-e. Representative images of flies at pupal stage P15 expressing either MECPFL (c), 
R294X (d), or both alleles (e) under the control of C380-GAL4. Histograms show the percentage 
of preparations with either 0, 1, or 2 MN5 somata present at P15 for each genotype. Both MN5 
somata and no cPARP reactivity was found with control (b) or MECP2FL (c). At P15, most MN5 
somata expressing either R294X alone (d) or together with MECP2FL (e) were gone, and high 
cPARP reactivity was found in the remaining somata and neuronal projections. Single asterisks 
indicate intact MN5 somata, double asterisks indicate absent or severely deteriorated somata. 
Scale bar depicts 10 μm. 
 
 74 
 
Figure 14. Timeline of apoptosis in MN5 with R294X expression 
a-d. Representative images of cPARP reactivity in MN5s at various pupal stages. C380-GAL4 
driven expression of transgenes begins at early P5, but no caspase activity was observed up to 
stage P10. Apoptosis appears to begin between stages P10-P12, but timing is variable between 
preparations. MN5 somata were completely missing as early as P12 and were always completely 
gone 24 hours after pupal eclosion. Scale bar depicts 10 μm. 
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R294X gain-of-function increases MECP2 induced apoptosis in cell culture 
While increased expression of MECP2 has been shown to enhance apoptosis in various 
cell lines and in primary neuron cultures (Bracaglia et al., 2009; Dastidar et al., 2012), effects of 
truncated MECP2 have not been directly investigated in mammalian systems. To test whether 
R294X contributes to apoptosis in a system with endogenous MECP2 expression, we transfected 
HEK293T cells with GFP tagged R294X, MECP2FL, or control vector. Consistent with previously 
published data (Bracaglia et al., 2009; Dastidar et al., 2012), overexpression of MECP2FL 
increased the number of apoptotic cells as compared to GFP-transfected controls (Figure 15a-b). 
Transfection with R294X, however, led to a significantly greater increase in cell death despite 
similar protein expression levels (Figure 15a-c). R294X expression therefore causes apoptosis in 
both Drosophila motoneurons and cultured HEK293 T cells.  
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Figure 15. R294X transfection promotes cell death in mammalian cell culture to a higher 
degree than MECP2FL. 
a. Representative images of HEK293T cells transfected with GFP tagged MECP2FL or R294X. 
Examples of healthy transfected cells are at left, while the condensed and/or fragmented nuclei at 
right were counted as apoptotic. b. Quantification of apoptotic cells following transfection of 
MECP2FL, R294X, or GFP control. n = 6 independent transfections/group, with > 400 cells 
counted for each independent transfection. Percentage data was transformed using the arsine 
square root function to meet the assumptions for a one way ANOVA (F(2,15) = 46.81, p < .0001). 
* p < .05, ** p < .01, *** p <.001 Tukey post-hoc test. c. Relative MECP2 expression 24 hours 
following transfection into HEK293T cells. No differences were observed in relative protein levels 
at 24 or 48 hours post-transfection (Mann-Whitney U test). Scale bar depicts 5μm. pi = propidium 
iodide, NS = not significant. 
 
 
 
 
 
 
 
 
 
 77 
Apoptosis as caused by C-terminal truncation is not mediated by a known functional 
domain 
 
Upon establishing validity of the Drosophila model system, we sought to use this system 
to determine which region of the missing 192 amino acids accounts for the critical phenotypic 
difference between R294X and MECP2FL. While the entire CTD is missing in the R294X allele, 
this mutation also disrupts the TRD by deleting the last 16 amino acids. Additionally, a proline-rich 
WW domain binding region (WWBR) has been identified spanning much of the CTD, from AA 
325-486 (Buschdorf & Strätling, 2004). While this domain can directly interact with the WW 
domains of RNA binding proteins, its function is not well understood (Buschdorf & Strätling, 
2004). In addition to S80, MECP2 has activity dependent phosphorylation sites located in CTD at 
S421 and S424 (Tao et al., 2009; Zhou et al., 2006). Both phosphorylation sites are located within 
one of two predicted PEST domains (Thambirajah, Eubanks, & Ausió, 2009), which are generally 
associated with rapid proteolytic degradation (Rechsteiner & Rogers, 1996). To test whether the 
apoptotic effect was mediated by one of these known functional regions of MECP2, we generated 
transgenic flies expressing three newly engineered C-terminal truncations: V312X (with intact 
TRD but truncated CTD), K431X (truncation beyond the predicted C-terminal PEST domain), and 
V481X (truncation eliminating the last five amino acids of the WWBR). New flies, including also 
new MECP2FL and R294X transgenes, were made using PhiC31 mediated site specific 
integration into the Attp2 landing site on chromosome III (Groth et al., 2004) to eliminate the 
possibility of positional effects due to transgene insertion site. All new constructs expressed in 
MN5 under the control of the C380-GAL4 driver with proper nuclear localization (Figure 16a). 
We observed caspase activity and cell death in MN5 with expression of both V312X and 
K431X (Figure 17a-c), but not with V481X or MECP2FL (Figure 17d-e). This suggests that the 
CTD between amino acids 431-481 accounts for the critical difference in cell death (Figure 17f). 
Thus apoptosis cannot be rescued by replacement of intact TRD or PEST domains, and an intact 
WWBR is not required for MN5 survival. We found no differences in relative MECP2 protein 
levels with quantitative Western blots from fly heads following pan neuronal expression of either 
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MECP2FL or the K431X variant, verifying that the observed effects are unlikely caused by 
variable protein levels (Figure 16b). 
 
 
Figure 16. New MECP2 transgenes localize to the nucleus and are expressed at relatively 
similar levels. 
a. Representative images of Drosophila MN5s (from pupal stages P8-P15) expressing MECP2FL 
or C-terminal truncated alleles. Transgenic flies were generated using phiC31 site-specific 
integration into the attp2 landing site to control for possible positional effects on transgene 
expression. b. Representative Western blot and densitometry analysis of normalized relative 
MECP2 levels in fly brain following pan neuronal expression of MECP2FL or the K431X 
truncation. No significant differences were detected (Student’s t-test). N = 4/group, each N 
consists of ten pooled fly heads. Scale bar depicts 10 μm. 
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Figure 17. MECP2 C-terminal domain is critical for preventing apoptosis in Drosophila 
MN5. 
a-e. Representative images of cPARP reporter activity in MN5 from flies expressing C-terminal 
truncated variants of MECP2 at pupal stage P15. All c-terminal truncations V481X (d) caused 
caspase mediated apoptosis in MN5. f. Schematic of MECP2 E2 isoform with mapped 
truncations. The region between 431-481 was found to be critical in preventing apoptosis as 
caused by truncated MECP2 in MN5. Scale bar depicts 10 μm. 
 
 
 
Serine 80 phosphorylation contributes to cell death in vivo 
In cell culture, phosphorylation at S80 has been shown to contribute to MECP2 related 
apoptosis (Bracaglia et al., 2009). Specifically, blocking S80 phosphorylation by an alanine 
substitution (S80A) reduces apoptosis while a phosphomimicking glutamate substitution (S80E) 
leads to increased apoptosis (Bracaglia et al., 2009). To determine whether MECP2 S80 
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phosphorylation contributes to apoptosis in vivo, we generated a transgenic fly line expressing 
with the phosphomimicking S80E substitution (MECP2FLS80E) as UAS-transgene. Expression of 
MECP2FLS80E increased cPARP reactivity, indicative of higher caspase activity, in adult MN5s 
at one day post-eclosion compared to normal MECP2FL (Figure 18a-b). Quantification revealed 
that following expression of MECP2FLS80E caspase activity in MN5 somata was significantly 
increased as compared to expression MECP2FL as a control (Figure 18d-e). However, although 
the phosphomimicking S80E substitution increased caspase activity, its effect was less severe as 
compared to c-terminal truncations. Consequently, MN5 somata of adult flies at 0-1 day with 
MECP2FLS80E were always present on both sides of the VNC (Figure 18f), whereas R294X 
caused most MN5 somata to die by this stage (Figure 13d). 
We further designed a new R294X allele with the S80A substitution to test whether 
phosphorylation at S80 is required for apoptosis as caused by C-terminal MECP2 truncation.  
Expression of R294XS80A caused apoptosis in MN5 to the same degree as R294X (Figure 18c). 
Thus, while MECP2 S80 phosphorylation likely contributes to apoptosis in vivo, or at least 
caspase activation, C-terminal truncations cause apoptosis independent of S80 phosphorylation 
status (see discussion).  
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Figure 18. S80 phosphorylation mediates caspase activity in full length but not truncated 
MECP2. 
a-c. Representative images of cPARP reporter activity in MN5. Intact MN5 cell bodies are 
outlined in white. b. Phosphomimicking mutation S80E increases caspase activity in MN5 
compared to controls (a), while phosphoblocking mutation S80A (c) has no effect on the toxicity 
of the R294X truncation. d. Percentage of preparations examined 0-24 hours post-eclosion with 
either 0,1, or both MN5s. e-f. Quantification of caspase activity visualized by 
immunocytochemistry. Individual MN5 somata (while dashed lines in a-b) were traced and mean 
grey values were calculated using ImageJ. Expression of MECP2FLS80E increased cPARP 
reactivity in comparison to expression of normal MECP2FL (f). No differences in VENUS 
reactivity were observed (e). *** p <0.001, Student’s two-tailed t-test, n=6 cells per group. Scale 
bar depicts 10 μm. 
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Co-expression of Slp1 delays apoptosis and improves motor behavior 
 In cultured mammalian neurons, promotion of neuronal death by the full length Mecp2-E2 
isoform is inhibited by forkhead protein FoxG1, and increasing FoxG1 can inhibit toxicity caused 
by increased Mecp2 (Dastidar et al., 2012). FoxG1 directly binds Mecp2 via a 20 amino acid 
sequence in its DNA binding domain (Dastidar et al., 2012), a region that is highly conserved in 
the Drosophila FoxG1 ortholog slp1 (Figure 19). To determine whether cell death in MN5 as 
caused by human R294X may be modified by the same mechanism, we co-expressed R294X 
with slp1 and assessed MN5 viability at one day post-eclosion. In comparison to R294X 
expression alone, which eliminated both MN5s in all preparations, all flies co-expressing slp1 
displayed at least one (33% of preparations), and more often both, MN5 somata at 1-2 days post 
eclosion (67% of preparations). However, even in flies with both intact MN5s cPARP 
immunoreactivity revealed high caspase activity throughout the somata and neuronal 
arborizations in either one or both MN5s at this time point (Figure 20a-b). This suggests that slp1 
only partially rescues the apoptotic effect of R294X. Statistical comparison of MN5s in all flies at 
1-2 days post-eclosion revealed a significant rescue with slp1 co-expression in comparison to 
R294X alone (Pearson’s chi-square = 36.00, p < 0.0001, Figure 20c). The slp1;R294X group was 
still statistically different from that with expression of MECP2FL (Pearson’s chi-square = 7.2, p < 
0.05, Figure 20c), thus supporting the qualitative partial rescue observed with the cPARP reporter 
(Figure 20a-b).   
We then tested whether the slp1 mediated partial rescue of R294X induced motoneuron 
death improved motor function. We used a well-established cylinder drop test (Banerjee, Lee, 
Venkatesh, Wu, & Hasan, 2004; Benzer, 1973; Venkiteswaran & Hasan, 2009) to test whether 
flies were able to initiate flight and land on the wall of a glass cylinder before falling 33 cm to the 
bottom of the cylinder. While not a single fly out of 40 expressing R294X alone were able to 
initiate flight, 57% of all flies co-expressing slp1 could fly (Figure 20 d). In accordance with our 
data on the cellular level, motor behavioral performance was only partially rescued. Although co-
expression of slp1 with R294X significantly improved flight initiation over R294X alone, the 
slp1;R294X group performed significantly worse as compared to flies expressing MECP2FL 
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(Figure 20d). Therefore, performance in this simple behavioral assay reflects previously identified 
genetic interaction and cellular phenotypes. This indicates that this tool may be useful in high 
throughput screening with the multiple genome wide transgenic available Drosophila libraries for 
future identification of novel players involved in the apoptotic function of MECP2 (see discussion).  
 
 
Figure 19. FOXG1/slp1 sequence alignment 
 
Alignment of the DNA binding domain of FOXG1 (human and mouse) with Drosophila ortholog 
slp1 shows high conservation in this sequence. The MECP2 binding region (234-254 of mouse 
Foxg1) as determined by (Dastidar et al., 2012) is outlined in black. 
 
 
 
 
 
 
 
 
 
 
Figure 20. Co-expression of slp1 improves cellular and behavioral consequences of R294X 
at one day post-eclosion. 
a-b. Representative images of cPARP reactivity in MN5s at 1-2 days post-eclosion. Single 
asterisks mark intact MN5s, while double asterisks denote absent MN5s. c. Distribution of 
preparations with 1, 2, or both MN5s is presented for flies expressing MECP2FL, R294X, or co-
expression of slp1; R294X. (* p < 0.05, *** p < 0.0001 Pearson’s chi square, n =18 flies/group). d. 
Percentage of flies failing to initiate flight in the cylinder drop test. Scale bar depicts 10μm. 
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Discussion 
Drosophila as a model system to study the role of MECP2 in apoptosis 
In this study, we used a Drosophila model of MECP2 gain-of-function to identify a critical 
role for the MECP2 CTD in cell survival.  Our data indicate for the first time that C-terminal 
truncating mutations of MECP2 cause neuronal apoptosis in vivo. Given that Drosophila lacks a 
common MECP2 ortholog and shows scarce genomic methylation (Capuano et al., 2014) it is 
clear that this model will not recapitulate all aspects of MECP2 related pathophysiology. However, 
multiple lines of evidence suggest that our novel findings in Drosophila are relevant to 
mammalian brains. First, we replicate our findings in HEK293T cell culture to confirm that C-
terminal truncation causes cell death in a mammalian system. Expression of the C-terminal 
truncation R294X significantly increases the apoptotic effect of the E2 isoform of full length 
MECP2 that was previously reported in cultured mammalian neurons (Dastidar et al., 2012). 
Second, in Drosophila, co-expression of the FoxG1 ortholog slp1 decreases the toxicity observed 
with MECP2 C-terminal truncations in vivo. FoxG1 is a known inhibitor of MECP2 toxicity in 
primary mammalian neuron cultures (Dastidar et al., 2012) and mutations in FoxG1 can also 
cause Rett related diseases  (Ariani et al., 2008; Jacob, Ramaswamy, Andersen, & Bolduc, 2009; 
Le Guen et al., 2011; Mencarelli et al., 2010; Philippe et al., 2010). Third, the apoptotic potential 
of full length MECP2 in Drosophila motoneurons is enhanced by serine 80 phosphorylation, as 
has been reported for numerous mammalian cell lines (Bracaglia et al., 2009).Together, our data 
suggest that C-terminal mutations can cause MECP2 to induce apoptosis, and that this specific 
function is conserved in Drosophila. While apoptosis has not been reported in vivo with MECP2 
C-terminal truncation or gain-of-function mouse models, MECP2 overexpression in chicken 
increases cell death in the developing neural tube (Petazzi et al., 2014). 
Generally, the molecular mechanisms underlying apoptosis are highly conserved from 
nematodes and insects to mammals (Green, 2000; O'Riordan, Bauler, Scott, & Duckett, 2008; 
Yuan, 1996), and MECP2 induced apoptosis in fly motoneurons can accordingly be ameliorated 
by co-expression of slp1, the Drosophila ortholog of mammalian FoxG1. Importantly, we show 
that this genetic interaction can be detected with a simple behavioral screen that can easily be 
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modified for high-throughput screening. This, combined with facile tools for genetic manipulation 
and the availability of transgenic and mutant fly lines for almost all genes (Venken & Bellen, 
2005), renders Drosophila a useful tool to identify additional factors involved in MECP2 related 
apoptosis. 
MECP2 C- to N-terminal interactions are likely required for healthy MECP2 function 
We found that truncations of the MECP2 C-terminus cause apoptosis in Drosophila MN5, 
and enhance the apoptotic role of the MECP2 E2 isoform in HEK293T cells. In Drosophila, this 
effect is replicated with truncated variants up to K431X, which eliminates only 55 amino acids of 
the CTD leaving intact TRD and PEST domains. Cells expressing the short V481X truncation, 
eliminating the last five amino acids of the WWBR, however, remain healthy. These data indicate 
that the CTD region between AA431-481 is critical for preventing MECP2 related apoptosis, but 
this is not caused by the loss of a critical health-promoting function of an identified functional 
domain.  
While the mechanism by which MECP2 C-terminal truncations cause apoptosis requires 
further investigation, we propose two explanations as to how this may occur. First, it is possible 
that MECP2 truncations, such as R294X, take on a new, divergent functions to initiate apoptosis 
pathways in vivo, such as binding to other proteins or DNA not normally influenced by MECP2FL. 
This may be supported by the fact that, when co-expressed with MECP2FL, R294X still causes 
apoptosis in MN5, exerting a dominant negative effect. However, the fact that increased 
expression of MECP2FL in cell culture causes cell death, albeit to a lesser extent than C-terminal 
truncated variants (Figure 15), (Bracaglia et al., 2009; Dastidar et al., 2012), suggests that it is 
unlikely to be an effect of a novel divergent function of the truncated protein. Alternatively, we 
propose that the C-terminus is instead critical for mediating healthy functions of MECP2 via 
internal interactions with the N-terminus.  
In support of the latter, previous in vitro studies have shown that phosphorylation at S80 
is required for apoptosis as caused by full length MECP2 (Bracaglia et al., 2009). This is in 
accordance to our finding that a MECP2 transgene with a phosphomimicking mutation at S80 
(MECP2FLS80E) also increases caspase activity in Drosophila motoneurons. However, we 
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further find that C-terminal truncations cause apoptosis independently of S80 phosphorylation 
status. This suggests that the effects of S80 phosphorylation may be upstream to the 
consequences of C-terminal truncation (Figure 21). This is consistent with a recent report on the 
role of the CTD in microRNA processing (Cheng et al., 2014). This study found that S80 
phosphorylation mediates internal N-C terminal interactions of MECP2. While N-C terminal 
interactions are increased by activity dependent de-phosphorylation of S80, they are decreased 
by constitutive S80 phosphorylation, and this in turn affects the ability of the CTD to bind other 
interacting proteins (Cheng et al., 2014).  
Therefore, our data best supports a model in which activity induced de-phosphorylation at 
S80 facilitates MECP2 N-C terminal interactions, which in turn mediate a “healthy” conformation 
of MECP2 promoting cell survival. Upon S80 phosphorylation, which is promoted in the absence 
of activity (Tao et al., 2009), N-C interactions are inhibited and the open MECP2 conformation 
activates apoptosis pathways (Figure 21). N-C terminal interactions are also eliminated by C-
terminal truncation of MECP2; thus, truncated variants remain in the “open” conformation 
regardless of S80 phosphorylation status (Figure 21). Intriguingly, FoxG1 binds with highest 
affinity to the N-terminal end of the MECP2-E2 isoform and elimination of the FoxG1 binding 
region also enhances apoptosis with MECP2 overexpression in primary neuron culture (Dastidar 
et al., 2012). Thus, it is possible that N-C terminal interactions facilitate the binding of FoxG1 (or 
Drosophila slp1) to MECP2, which in turn acts to suppress MECP2 neurotoxity. However, further 
experiments will be needed to test whether internal MECP2 N-C-terminal interactions promote 
cell survival. 
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Figure 21. Working model. 
 
Phosphorylation of MECP2FL at S80 induces conformational changes of MECP2 that prevent C- 
and N-terminal interactions (CT-NT interactions), thus inducing conformational changes that 
(apoptotic state, red) underlie the apoptotic effect of MECP2 in vivo. Calcium dependent de-
phosphorylation at S80 returns MECP2 to a healthy conformation (green) that allows CT-NT 
interactions. C-terminal truncation prevents CT-NT interactions thus favoring the apoptotic 
conformation of MECP2. R249X is shown as an example, but it is expected that V312X and 
K431X truncations act in the same manner. The short truncation V481X removes just 5 amino 
acids, which does not prevent CT-NT interactions thus favoring the healthy conformation of 
MECP2. 
 
MECP2, apoptosis, and disease 
 It remains an important question if and how the apoptotic function of MECP2 contributes to 
the pathophysiology of Rett Syndrome and other related neurodevelopmental disorders. 
Mutations such as R294X at, near, or beyond the end of the TRD, are seen with high frequency in 
Rett patients (Bedogni et al., 2014), and mouse models expressing MECP2 truncated variant 
MECP2308 exhibit symptoms recapitulating many features of Rett Syndrome (Shahbazian, Young, 
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et al., 2002; Young & Zoghbi, 2004). Remarkably, however, C-terminal truncating mutations are 
generally associated with less severe symptoms in human patients compared to mutations in 
other domains (Bebbington et al., 2008; Cuddapah et al., 2014; J. L. Neul et al., 2008; Schanen 
et al., 2004). This seems counterintuitive considering our findings that C-terminal truncations 
strongly increase the likelihood of apoptosis in neurons and HEK293T cells.  
An intriguing explanation for this discrepancy may be that neurons with C-terminal 
truncated variants of MECP2 may undergo apoptosis early in development. This would increase 
the proportion of neurons expressing the healthy MECP2 variant and potentially improve disease 
prognosis. Because MECP2 is located on the X-chromosome, most patients carry a healthy 
MECP2 allele along with the mutated variant. In most Rett patients, the X chromosome follows 
random inactivation patterns and the mutated allele is expressed in an approximately equal 
number of cells within the brain to the healthy allele (Amir et al., 2000; Hoffbuhr, Moses, 
Jerdonek, Naidu, & Hoffman, 2002; Shahbazian, Sun, & Zoghbi, 2002). Nonetheless, there are 
reports of non-random X inactivation in Rett Syndrome patients. The majority of the mutations are 
either truncating or missense mutations disrupting the TRD or C-terminus (Hoffbuhr et al., 2002; 
Huppke et al., 2006; Weaving et al., 2003). Although non-random X-inactivation has been 
suggested to potentially improve disease prognosis in asymptomatic or mildly symptomatic 
female carriers (Bienvenu et al., 2000; Lyon, 2002; Schanen et al., 1997), the underlying 
mechanisms are unknown. As an alternative explanation to non-random X-inactivation, we 
suggest that high rates of apoptosis of neurons with truncating mutations during early 
development may be the cause for improved disease prognosis. Consistent with this hypothesis 
and the established finding that increased MECP2 expression increases the likelihood of 
apoptosis, disproportionally high numbers of neurons expressing the healthy X-chromosome is 
standard in females carrying MECP2 duplications (del Gaudio et al., 2006; Van Esch et al., 2005). 
In mouse models, female mice heterozygous for the MECP2308 truncated allele show a 
high degree of skew towards expression of the healthy Mecp2 variant, which is correlated with 
severity of behavioral phenotypes (Young & Zoghbi, 2004). Primary neuron cultures taken from 
these mice support the idea that this may be due to apoptosis as caused by the truncated variant;  
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the proportion of cultured neurons expressing the healthy MECP2 allele over MECP2308  is 
increased over time, even when initially plated equally (Jiang et al., 2013). Further experiments 
examining apoptosis in early neural development with MECP2308 and MECP2TG overexpression 
mice will be needed to conclusively test this hypothesis in vitro and in vivo. 
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CHAPTER 5 
 
CONCLUSIONS 
 
Summary of Results 
 
 The primary goal of this work was to utilize a Drosophila model to help understand the 
pathophysiology associated with MECP2 gain-of-function. The first step in accomplishing this 
goal was to establish a Drosophila model in which the function of MECP2 in neurons can be 
empirically studied (Chapter 2), (Vonhoff et al., 2012). In collaboration with the additional authors 
of this study I found that expression of human MECP2 in the Drosophila flight motoneuron 5 
(MN5) led to a 50% reduction in total dendritic length and number of dendritic branches. This is 
the first study to show cellular effects of MECP2 gain-of-function in Drosophila neurons and 
provides face validity for the Drosophila model system as the cellular effects match those 
observed in post-mortem human brain tissue and in mouse models (Armstrong et al., 1995; 
Cheng et al., 2014; Jentarra et al., 2010; Zhou et al., 2006). In addition, dendritic defects are 
partially rescued by reducing the dose of the chromatin remodeling protein, osa, ortholog of a key 
component of the MECP2 associated SWI/SNF chromatin remodeling complex (Harikrishnan et 
al., 2005), confirming that the fly model can be used to detect conserved MECP2 genetic 
interactions.   
 In Chapter 3, I used the Drosophila MECP2 gain-of-function model and nonbiased RNA-
sequencing to identify genes involved in the dendritic growth phenotype. This approach identified 
20 genes with human orthologs differentially expressed with MECP2 gain-of-function. Notably, 
60% of these genes are regulated in the same direction as with MECP2 gain- or loss- of function 
in mouse as identified through similar arrays. MECP2 regulates the expression of hundreds of 
different genes in mouse (Ben-Shachar et al., 2009; Chahrour et al., 2008; Zhao et al., 2013), but 
the interaction and functional consequence of most altered genes has not been confirmed. 
Alternatively, the small list of genes identified in the fly model provided an approachable dataset 
in which genes could be analyzed and prioritized with a primary literature search. In this analysis, 
I found that 30% of the identified genes with mammalian orthologs interacted with the Hippo 
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signaling pathway (Chapter 3, Figure 7), linking this pathway for the first time to MECP2. This 
finding was important for two reasons: first, Hippo Signaling has an identified role in dendritic 
growth, maintenance, and organization (Emoto et al., 2006; Parrish, Emoto, Jan, & Jan, 2007; 
Ultanir et al., 2012; Yang et al., 2011) and therefore could be a critical pathway involved in 
MECP2 related impaired dendritic morphology. Second, Hippo signaling has been associated 
with other neurological disorders with cognitive dysfunction, including schizophrenia and 
Alzheimer’s disease (Melka et al., 2015; Orcholski et al., 2011; Plouffe et al., 2015). Hippo 
signaling regulates Wnt/β-catenin signaling (Varelas et al., 2010), a pathway strongly linked to 
autism spectrum disorders (reviewed in (Kalkman, 2012)). Thus, disruption of the Hippo signaling 
pathway by MECP2 gain- (and potentially also loss) of-function could explain some of the shared 
behavioral features between RTT, MDS, autism spectrum disorders, and other neuropsychiatric 
or neurodegenerative diseases. 
The human memory associated gene KIBRA was selected as a top candidate gene 
identified in the RNA-Seq screen due to its position as an activator of the Hippo Signaling 
pathway.  In the second part of Chapter 3, I validated that KIBRA was increased with MECP2 
gain-of-function in both the fly brain and in mouse primary neuron culture. Additionally, I found 
decreased Kibra in the brain of MECP2-/Y mice indicating that KIBRA is bidirectionally regulated 
by MECP2. Knockdown of kibra in Drosophila rescued the dendritic defects caused by MECP2 
gain-of-function, suggesting a functional role for kibra and Hippo signaling in the pathogenesis of 
impaired dendritic morphology.  
In Chapter 4, I used the Drosophila model system to probe an additional cellular 
phenotype caused by MECP2 gain-of-function in neurons. While MECP2 gain-of-function has 
been shown to enhance apoptosis in neuron culture (Bracaglia et al., 2009; Dastidar et al., 2012), 
I report for the first time that expression of C-terminal truncating mutations can cause apoptosis in 
neurons. I then identified a 50 amino acid region within the C-terminal domain that is critical in 
mediating this effect. Gain-of-function of the truncated variant R294X in HEK293T cells enhanced 
apoptosis to a higher degree than full-length MECP2 providing validation in a system with 
endogenous MECP2 expression. I additionally report that, as in mammals, the effect of MECP2 
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on apoptosis in the fly is mediated by phosphorylation at Serine 80 (S80) and FoxG1 ortholog 
Slp1. Considering that late truncating or frameshift mutations account for at least 25% of RTT 
causing mutations (Bedogni et al., 2014), this finding could be important in understanding how 
such mutations affect the pathophysiology of Rett Syndrome (See Chapter 4 discussion). 
 
Translational Validity of the Drosophila MECP2 Gain-of-Function Model 
 As described in the introduction to this dissertation, there are several advantages to 
working with Drosophila as a model system for human disease related research (Pages 6-8). 
Prior to the work presented here, however, it was unclear whether Drosophila could be used to 
study MECP2 gain-of-function at the cellular level and whether findings would be translatable to 
systems with endogenous MECP2. In this dissertation, I provide the following evidence in support 
of both: First, the observed dendritic phenotype and the functional rescue by the ortholog of an 
interactor identified in mammals provides face validity of the model at the cellular level (Chapter 
2). Second, 60% of the genes identified by RNA-Seq are regulated by MECP2 in the same 
direction in mouse models (Chapter 3). Third, the novel identification of Kibra as a target of 
MECP2 was validated in mouse primary neuron culture and in vivo with a MECP2 knock-out 
mouse model (Chapter 3). Fourth, apoptosis caused by MECP2 C-terminal truncation was 
validated a mammalian cell culture with endogenous MECP2 expression (Chapter 4). Finally, as 
in mammalian cell culture, apoptosis caused by MECP2 in vivo can be modified by manipulation 
FoxG1 ortholog slp1 and S80 phosphorylation. Together, the work presented in this dissertation 
provides substantial evidence supporting the utility of the fly model as a translational model for 
MECP2 gain-of-function in neurons 
 
Limitations of the Drosophila model of MECP2 Gain-of-Function in Neurons 
 Despite the numerous advantages of Drosophila as a model organism, there are several 
noteworthy limitations to using this system. First, due to the lack of a common ortholog, one must 
always rely on expression of human MECP2. Thus, there is always the possibility that results 
obtained with the Drosophila model system could be attributed to a nonspecific effects resulting 
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from heterologous expression and not a direct function of MECP2. Results obtained using 
Drosophila will therefore always ultimately require validation in systems with endogenous 
MECP2. Furthermore, loss-of-function MECP2 mutations are a far more common cause of 
human disease than gain-of-function mutations (Christodoulou et al., 2003), but the external 
validity of the system to study such mutations is questionable. While induced expression of 
known MECP2 loss-of-function mutations is possible in the fly, this system can only be used to 
identify new or enhanced activities caused by mutation such as neuronal apoptosis with R294X 
expression (Chapter 4). Lost functions due to the mutation, however, cannot be identified. 
Accordingly, in Chapter 2 I report that two RTT linked mutations, R106W and Δ166, have no 
effect in Drosophila neurons. In addition, because the Drosophila genome is only scarcely 
methylated (Capuano et al., 2014; Dunwell & Pfeifer, 2014; Takayama et al., 2014), any functions 
mediated by the methyl-DNA binding function of MECP2 cannot be investigated with this model. 
The role of genomic methylation in the effects of MECP2 on transcriptional repression has been 
well described and supported (Jones et al., 1998; Lewis et al., 1992; Lombardi, Baker, & Zoghbi, 
2015; Lyst & Bird, 2015; Nan et al., 1997). Our data provide additional support for this as 95% of 
the genes identified by RNA-Seq in Chapter 3 were activated by MECP2 instead of repressed. 
Thus, while the system can be used to study functions not related to methylated DNA binding, 
MECP2 gain-of-function in Drosophila cannot be used to understand the pathogenesis of all 
relevant symptoms and pathology. 
  
Unresolved Issues and Future Directions 
 Despite clear translational validity of Drosophila as a model system to study MECP2 
gain-of-function in neurons, an important question remains: In the absence of DNA methylation 
dependent epigenetic regulation of transcription, how does MECP2 function in they fly? While this 
remains to be empirically determined, I propose two mechanisms by which this could occur. First, 
it is possible that MECP2 still acts at the genomic or epigenomic level to regulate transcription. In 
Chapter 2, I report that the dendritic effects of MECP2 gain-of-function in Drosophila 
motoneurons are dependent on an intact methyl-binding domain (MBD).  While there is no 
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MECP2 ortholog, the Drosophila genome encodes other proteins containing MBDs likely due to 
the role of the MBD in binding histone modifications (Bartke et al., 2010; Fuks et al., 2003). 
MECP2 can directly bind methylated histones (Fuks et al., 2003) and influence local gene 
expression both in the presence and absence of genomic DNA methylation (Zhao et al., 2005). 
Comparative analysis of patterning and regulatory association of DNA methylation and histone 
modifications in insects has revealed that active histone methylation in Drosophila is localized in 
genomic regions with conserved DNA methylation in both fire ants and honey bees, insects with 
higher overall levels of genomic methylation (Hunt, Glastad, Yi, & Goodisman, 2013). Thus, 
histone modifications may be in some degree redundant to other forms of epigenetic information 
and binding of MECP2 to methylated histones in Drosophila could influence the same genes as 
when bound to methylated DNA. This may explain why MECP2 can still activate genes in the 
absence of DNA methylation but to a lesser degree than in the presence of methylation (Chen et 
al., 2013). MECP2 can also bind non-methylated DNA (Georgel et al., 2003; Ghosh et al., 2010; 
Hansen et al., 2010; Nikitina et al., 2007) and has been found enriched at active, partially 
unmethylated promoter regions (Yasui et al., 2007), but it is unknown if and how this binding 
effects transcription. Finally, while genomic methylation in Drosophila is scarce, it is possible that 
some of the observed effects of human MECP2 could be attributed to binding of the ~1% of the 
genome with dynamic DNA methylation (Takayama et al., 2014). Interestingly, the scarce 
methylated regions within the Drosophila genome are CA- and CT- rich but guanine deficient 
(Takayama et al., 2014). Thus, even if MECP2 binds to Drosophila methyl-CpA/T regions, it is 
may not act via the same mechanisms as when bound to methyl-CpG. MECP2 binding to methyl-
CpA/T regions has only recently been described and is still not well understood (Gabel et al., 
2015; Guo et al., 2014). In summary, it is possible that MECP2 can activate transcription of the 
same genes in Drosophila as in mammals by binding methyl CpA/T regions, methylated histones, 
and/or non-methylated DNA.  
 Alternatively, the effects of MECP2 in the fly may be due to functions beyond the 
chromatin level. In additional to transcriptional modification, MECP2 has been shown to interact 
with RNA in vitro (Jeffery & Nakielny, 2004) and can work with other RNA binding proteins to 
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mediate processes such as RNA splicing (Young et al., 2006) or microRNA processing (Cheng et 
al., 2014) and may regulate genes at the post-transcriptional level in Drosophila. Notably, MECP2 
gain-of-function dendritic growth defects in mouse primary neuron culture can be rescued by 
restoring an affected microRNA (Cheng et al., 2014), and MECP2 could therefore act by 
influencing similar microRNAs in Drosophila. In addition, other diverse MECP2 binding partners 
have been identified (Reviewed in (Lyst & Bird, 2015)) but, for many, the functional significance is 
unknown. It is possible that these interactions may mediate additional unknown functions of 
MECP2, and the cellular changes with gain-of-function in the fly are downstream effects of these 
functions. The proposed explanations for how human MECP2 functions in Drosophila are not 
mutually exclusive, and it is likely that the effects are due to a combination of the described 
and/or other unknown functions. Future experiments to determine the mechanism by which 
MECP2 acts with heterologous expression in Drosophila neurons will be important to fully 
understand the utility and limitations of this model system.   
Further experiments will additionally be needed to address the unanswered questions 
introduced in Chapter 3 and Chapter 4. In Chapter 3, I show that Kibra is bidirectionally regulated 
by MECP2. It remains unclear, however, how MECP2 acts at the molecular level to influence 
Kibra mRNA and protein levels. Further experiments will be needed to determine whether 
MECP2 binds to the Kibra genetic locus and directly mediates gene expression, or whether 
changes in Kibra are secondary to other MECP2 targets and/or functions. Interestingly, a direct 
physical interaction between Kibra and MECP2 is possible via the WW domain of Kibra and the 
WW binding region of MECP2. Kibra is primarily localized at the post-synapse, but it is also 
present in the nucleus where it could interact directly with MECP2 (Hilton et al., 2008). However, 
it is unlikely that a direct physical interaction mediates the changes in Kibra with MECP2 loss- or 
gain- of function as increased kibra was not observed with the MBD point mutated R106W 
variant. The WW binding region of this variant is fully intact, and should therefore be available to 
interact with Kibra to the same extent as full-length MECP2. Nonetheless, a direct physical 
interaction between MECP2 and Kibra could still hold physiological relevance within the nervous 
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system. Future experiments will be needed to conclusively determine how MECP2 and Kibra 
interact within the cell, and how this interaction is involved in dendritic growth. 
In Chapter 3, I additionally show that increased kibra is necessary for MECP2 induced 
dendritic growth defects, but not sufficient to independently impair dendritic morphology. This 
finding highlights the potential of KIBRA as a future therapeutic target, but raises an additional 
question. Why does increasing kibra in the absence of MECP2 have no effect on dendritic 
pathology? I hypothesize that kibra works with additional factors in the presence of MECP2 to 
cause cellular defects, but this will need to be empirically tested either in Drosophila, mouse 
primary neuron culture, or both. In addition to kibra, we identified eleven other genes increased 
with full length MECP2 expression, but not with the MBD mutation variant R106W, in Drosophila 
that have also been identified by microarray analyses in mouse models (see Figure 6). Thus, it is 
possible that upregulation of one or many of these genes is required along with kibra for 
disrupting normal dendritic growth in the presence of MECP2. Several of these targets act on the 
Hippo signaling pathway (see Figure 7), but none are known to interact directly with Kibra. 
However, additional analysis of the RNA-Seq data presented in Chapter 3 revealed an additional 
candidate gene that could provide a more direct explanation of this somewhat paradoxical finding. 
In addition to the changes in total gene expression presented in Chapter 3 and Appendix A, 
further analysis of this data revealed considerably more genes with changes only in expression of 
specific isoforms (Appendix B). One such gene, aPKC (or mammalian orthologs PRKCI/PRKCZ), 
directly interacts with KIBRA by phosphorylating it at serines 975 and 978 (Büther, Plaas, 
Barnekow, & Kremerskothen, 2004). Interestingly, aPKC also interacts directly with the Hippo 
signaling pathway (Grzeschik, Parsons, Allott, Harvey, & Richardson, 2010) and specific isoforms 
of the mammalian aPKC orthologs have described functions in synaptic plasticity, learning, and 
memory (Boehm et al.; Hernandez et al., 2003; Ling et al., 2002; Ren et al., 2013). It is possible 
that phosphorylation of kibra by aPKC is critical for regulating its involvement in dendritic growth. 
Thus, in the presence of MECP2, upregulation of both kibra and a specific aPKC isoform is 
required for the observed dendritic growth defects. Inhibiting the increase in kibra alone should 
therefore block the growth defects as observed. Accordingly, increasing kibra in the absence of 
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MECP2 should therefore have no effect on dendritic growth without also manipulating aPKC. 
Future experiments will be needed to test whether increasing both kibra and aPKC could 
therefore phenocopy the effects of MECP2, and which aPKC isoform is critical for mediating this 
interaction. Furthermore, the role of the other candidate genes and isoforms identified by the 
RNA-Seq experiments remains to be determined.  
 In Chapter 4, I show that C-terminal truncating MECP2 mutations cause apoptosis in 
Drosophila motoneurons and propose that MECP2 N-C terminal interactions mediate neuronal 
survival (see Figure 21). However, the mechanism by which N-C terminal interactions mediate 
survival remains to be determined. One possibility is that such interactions facilitate the binding of 
the highly conserved FoxG1 (Drosophila slp1) DNA binding domain (see Figure 19) to the 
MECP2 N-terminus. Increasing FoxG1 or slp1 improves neuronal survival in cell culture (Dastidar 
et al., 2012) and in vivo (Chapter 4) but it is unclear whether this results from an increase in the 
reported physical interaction between FoxG1 and MECP2 (Dastidar et al., 2012). An alternative 
option is that MECP2 N-C terminal interactions interfere with MECP2-FoxG1 binding, and thus 
free FoxG1 to promote cell survival. This option is supported by the finding that only the MECP2-
E2 variant is involved in neuronal apoptosis (Dastidar et al., 2012). Increasing MECP2-E1, which 
lacks the N-terminal region that binds to the FoxG1 DNA binding domain, has no impact on 
neuronal survival, whereas increasing MECP2-E2 enhances cell death in primary cerebellar 
granule neuron culture (Dastidar et al., 2012). Thus, increased physical interactions between 
MECP2 and FoxG1/slp1 could cause the enhanced toxicity and, in the presence of activity and 
absence of S80 phosphorylation, displacement of this interaction by the MECP2 C-terminus could 
promote cell survival. While FoxG1 alone promotes neuronal survival downstream of neurotrophic 
factor IGF-1 and Akt kinase (Dastidar et al., 2011), its downstream targets are unknown. Further 
experiments will be needed to determine how MECP2 and FoxG1/slp1 function both together and 
independently to conclusively determine the mechanism by which MECP2 acts to mediate 
neuronal apoptosis. 
 Finally, in Chapter 4 I present the hypothesis that enhanced apoptosis caused by C-
terminal truncating mutations may lead a higher proportion of neurons with the mutated allele 
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inactivated, and therefore improve symptomatic severity in Rett syndrome patients carrying these 
alleles. Clinical literature evaluating X-inactivation status in patients with truncating mutations is 
scarce, but there are examples of both normal (Colantuoni et al., 2001) and skewed (Hoffbuhr et 
al., 2002; Huppke et al., 2006; Weaving et al., 2003) X-chromosome inactivation in patients 
carrying MECP2 C-terminal truncating mutations. A more thorough evaluation of X-chromosome 
inactivation among Rett syndrome patients will be needed to conclusively determine whether 
patients with such mutations show a higher degree of skewed inactivation in comparison to 
patients with mutations affecting other MECP2 domains. Furthermore, while female mice 
heterozygous for the MECP2308 truncated allele show a high degree of skew towards expression 
of the healthy Mecp2 variant (Young & Zoghbi, 2004), it is not clear whether this is caused by 
enhanced apoptosis. MECP2 contributes to apoptosis in the developing chick neural tube 
(Petazzi et al., 2014), but this has not yet been supported by in vivo data from MECP2 loss- or 
gain- of function mouse models. Systematic evaluation of apoptosis and X-chromosome 
inactivation patterns throughout all stages of brain development in MECP2 duplication and 
MECP2308 mice will be needed to conclusively determine whether MECP2 contributes to 
apoptosis in vivo and whether this is enhanced by C-terminal truncating mutations.  
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a. List of genes differentially expressed with pan neuronal human MECP2 expression in 
the adult fly brain 
Flybase ID Human orthologs 
log2- 
Fold 
Change 
FDR 
corrected 
pvalue 
Mouse array 
matches 
Genes with identified human orthologs    
arr2 
ARRB2, ARRB1, SAG, 
ARR3 1.610 0.001 
ARRB2 in hyp., SAG 
in hipp. (9wk) 
CG5966 
PNLIP, PNLIPRP1, 
PNLIPRP3, PNLIPRP2 3.377 0.004 
PNLIPRP2 in hipp. 
(4wk) 
pepck PCK2, PCK1 1.676 0.004 PCK2 in hyp. 
rh2 COMMD2, OPN4 1.377 0.007 OPN4 in hipp. (4wk) 
pi3k92e 
PIK3CD,  PIK3CB, 
PIK3CA, PIK3CG 1.385 0.008 PIK3CG in hyp. & cb. 
CG11486 PAN3 1.580 0.008 
PAN3 in hipp. (4 & 9 
wk) 
cka STRN4, STRN, STRN3 2.022 0.013 STRN4 in hyp. 
sox21b SOX14, SOX21, SOX12 1.464 0.024 SOX 12 in cb. 
dysc DFNB31, PDZD7 1.242 0.040 
PDZD7 in hyp. & 
hipp. 
ppt2 PPT2, EGFL8 1.716 0.042 PPT2  in hyp.  
arpc1 ARPC1A, ARPC1B 2.546 0.042 ARPC1A in hyp. 
kibra WWC1 (KIBRA), WWC2 1.217 0.049 WWC1 in cb. 
CG3328 MYRF, MYRFL 1.743 0.001   
CG6287 PHGDH 1.722 0.001   
hr4 NR6A1  2.706 0.003   
impL3 LDHA, LDHB, LDHAL6A 2.988 0.025   
CG7332 FAM188A 1.278 0.027   
sec31 SEC31A, SEC31B 1.428 0.049   
CG18095 LRRTM3  6.330 0.050   
CG3625 AIG1, ADTRP -1.490 0.011   
Genes without identified human orthologs    
irc   1.971 0.000   
CG13722   3.990 0.002   
CG11697   2.115 0.005   
CG14982   1.570 0.006   
mtk   5.463 0.015   
CG32240   7.373 0.024   
drs   4.017 0.033   
CG15784   3.527 0.042   
CG10332   5.878 0.049   
totA   -3.743 0.000   
totC   -7.476 0.040   
fok   -1.250 0.040   
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b. List of genes differentially expressed with hR106W expression, but not  hMECP2FL 
Flybase ID Human orthologs 
log2- 
Fold 
Change 
FDR 
corrected 
p 
Mouse array 
matches 
Su(Ste):CR42418  -2.921 0.000   
bt TTN -1.695 0.016  
          
c. List of genes differentially expressed with both hMECP2 and hR106W expression 
Flybase ID Human orthologs 
log2- 
Fold 
Change 
FDR 
corrected 
p 
Mouse array 
matches 
socs16D SOCS7 1.705 0.000 SOCS7 in hyp. 
CG12241 SGSM3 1.842 0.001   
CG7582 TMEM86A, TMEM86B 1.543 0.012   
CR40712   -2.624 0.000   
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List of genes differentially spliced with pan-neuronal human MECP2, but not hR106W,  
expression in the adult fly brain 
Flybase ID Human orthologs 
Direction of 
change in 
transcript 
abundance 
FDR-
correct
ed P  
Orthologs 
present in 
mouse array 
data 
CG11897 
ABCC4, ABCC5, 
ABCC8 decrease 
0.014 
ABCC4 in cb. & 
hyp.  
CG2765 MID1IPI, THRSP  decrease 0.015  
CG3744 DPP9, DPP8 decrease 0.044  
NTPase ENTPD5, ENTPD6 decrease 0.025  
CG13124 MIF4GD, CTIF  decrease 0.049  
Oda OAZ2, OAZ1, OAZ3 decrease 0.022  
Sh3beta 
SH3BGR, 
SH3BGRL2, 
SH3BGRL,  decrease 
0.032 
 
Trn TNPO1, TNPO2 decrease 0.010  
Ubp64E USP 47 decrease 0.019  
CG14853 ERICH2 decrease 0.034   
MED26 MED26, CALR3 decrease 0.002   
NetB NTN1, NTN3, NTN5 decrease 0.002   
l(2)37Cc PHB decrease 0.036   
CG1732 SLC6A1 decrease 0.027   
CG13800 SVIL decrease 0.018   
isopeptidase-
T-3 UBAC1 decrease 
0.007 
  
CG8878 VRK3, VRK1, VRK2  decrease 0.036   
rn   decrease 0.046   
pHCl   decrease 0.018   
CCHa2   decrease 0.012   
CG32700   decrease 0.009   
Abi ABI2, ABI1, ABI3  increase 0.007 ABI3 in cb. 
arm CTNNb1, Jup increase 
0.017 
CTNNB1 hyp., 
jup in hyp. 
l(1)G0232 ptpn9 increase 
0.029 
PTPN9 in hyp. & 
cb. 
CG2017 GTPBP2, GTPBP1 increase 0.035 GTPBP2 in hyp. 
Shal 
KCND2, KCND3, 
KCND1 increase 
0.037 
KCND1 in hyp. 
Tsf1 MFI2, TF, LTF  increase 0.038  
didum 
MYO5A, MYO5B, 
MYO5C increase 
0.033 
MYO5b in hyp. 
ninaE 
OPN4, OPN1LW, 
OPN3  increase 
0.010 
OPN3 in cb. 
rdgB PITPNM1, PITPNM3  increase 0.000 PITPNM1 in hyp. 
PKD 
PRKD3, PRKD1, 
PRKD2 increase 
0.042 
PRKD2 in hyp. 
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Flybase ID Human orthologs 
Direction of 
change in 
transcript 
abundance 
FDR-
correcte
d P  
Orthologs present 
in mouse array 
data 
PTP-ER 
PTPN5, PTPRR, 
PTPN7  increase 
0.039 
PTPN5 in hyp. 
srpk79D 
SRPK3, SRPK1, 
SRPK2 increase 
0.030 
SRPK3 in hyp. 
gro TLE3, TLE4, TLE1 increase 
0.038 
TLE3 in hyp., TLE1 
in hyp. 
CG7611 WDR26 increase 0.001 WDR26 in hyp. 
Su(dx) ITCH, WWP2, WWP1 increase 
0.034 
WWP1 in hyp., 
WWP2 in hyp.,  
CG14995 C21ORF2 increase 0.048   
CG4678 
CPM, CPE, CPD, 
CPN1 increase 
0.030 
 
Dscam3 DSCAM, DSCAML1  increase 0.040   
CG32085 FBXL16 increase 0.035   
h HES4, HES1 increase 0.015   
CG11138 
IRF2BP2, IRF2BPL, 
IRF2BP1  increase 
0.048 
  
Strn-Mlck MYLK  increase 0.045   
Mhcl MYO18A, MYO18B increase 0.033   
ptip PAXIP1, MDC1 increase 0.025   
aPKC PRKCI, PRKCZ increase 0.036   
nocte PRRC2B, PRRC2A increase 0.010   
CG34408 RALGAPB increase 0.024   
Rcd-1 RQCD1 increase 0.036   
CG4266 SCAF4, SCAF8 increase 0.026   
Aats-thr TARS, TARsl2, Tars2  increase 0.000   
mus210 XPC increase 0.029   
YT521-B YTHDC1 increase 0.045   
lcs   increase 0.009   
CG17612   increase 0.034   
Eh   increase 0.033   
CG7337   increase 0.036   
CG15443   increase 0.022   
chas   increase 0.033   
to   increase 0.033   
CG18067   increase 0.039   
CG10508   increase 0.042   
CG4297   increase 0.042   
CG17816   increase 0.033   
CG13800   increase 0.017   
CG32240   increase 0.001   
CG16826   increase 0.014   
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List of isoforms differentially expressed with pan-neuronal human R106W expression, 
but not with MeCP2FL 
Flybase ID Human orthologs 
Direction of 
change in 
transcript 
abundance 
FDR-
correcte
d P  
Orthologs present 
in mouse array 
data 
Cyp9f2 
CYP3A43, CYP3A4, 
CYP3A5,  Decrease 
0.000 
  
tim TIMELESS decrease 0.000   
sls   decrease 0.002   
CG7668   increase 0.005   
ago FBXW7 increase 0.008  
CG14476 GANAB, GANC increase 0.014 GANAB in hyp. 
CG33981 ANAPC13 increase 0.017   
MTF-1 MTF1 increase 0.018   
Nmdar2 
GRIN2D, GRIN2C, 
GRIN2B, GRIN2A increase 
0.018 
GRIN2D in hyp.,  
CG16970   decrease 0.022   
Camta CAMTA2, CAMTA1 increase 0.028 CAMTA2 in hyp. 
Rab40 
RAB40C, RAB40B, 
RAB40A, decrease 
0.029 
 
CG2246 PRPSAP2, PRPSAP1 increase 0.029   
CG12024 CUEDC1 increase 0.031   
thoc7 THOC7 increase 0.031   
ttk   decrease 0.033   
EloA 
TCEB3, TCEB3B, 
TCEB3C, TCEB3CL2, 
TCEB3CL 
increase 
0.033 
  
stv BAG3, BAG4, BAG5 increase 0.034   
Akh   increase 0.034   
prominin-like PROM1, PROM2 increase 0.036   
Cdc42 Cdc42 decrease 0.036   
CG11147   decrease 0.036   
CG10680   increase 0.036   
brm SMARCA4, SMARCA2 increase 0.041   
Ars2 SRRT increase 0.044   
Ptp61F PTPN1, PTPN2 increase 0.045 PTPN2 in cb. 
CG2918 HYOU1 decrease 0.045   
CG7120   increase 0.048   
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